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Abstract
Over the past 35 years the development of strategies that allow to automatically control the
patient neuromuscular blockade (NMB) has met some important advances. This development
allowed the evolution from a simple on-off controller to intelligent control schemes based on a
variety of theories, such as the adaptive and model-based controllers.
Despite the vast work previously done in the area of NMB control, some problems still exist,
like a very high degree of uncertainty in the system dynamics due to the intra- and intervariability
in the patients and nonlinearities, and it is still desirable to achieve a better anesthetic solution.
Therefore further study around this theme in order to overcome the drawbacks of the manual
control as well as the limitations of the previous NMB control strategies will have a high impact
in the anesthetic community.
This work presents the implementation of a model-based switching control strategy to drive
the NMB level of patients undergoing general anesthesia to a predefined reference. SISO (Single-
Input-Single-Output) Wiener models with a compartmental part, describing the pharmacokinet-
ics and pharmacodynamics linear effect together with a static nonlinearity are used to model the
NMB response of two muscle relaxants, atracurium and rocuronium. The switching controller is
designed based on a bank of total system mass control laws, where each of such laws is tuned
for an individual model from a bank of models developed to represent the behavior of the whole
population. Moreover a scheme to improve the reference tracking quality based on the analysis
of the patient’s steady-state response is presented.
Keywords: Automatic NMB Control, Compartmental Models, Switching Control, Total
System Mass Control Law, Reference Tracking Improvement.
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Resumo
Durante os u´ltimos 35 anos o desenvolvimento de controladores que permitem o controlo do n´ıvel
de bloqueio neuromuscular (NMB) de um paciente tem conhecido importantes avanc¸os. Grac¸as
a estes desenvolvimentos foi poss´ıvel evoluir desde simples controladores on-off ate´ controladores
inteligentes baseados numa larga gama de teorias, tais como os controladores adaptativos e os
controladores baseados em modelos.
Apesar do enorme volume de trabalho que se tem vindo a desenvolver na a´rea do controlo do
NMB, ainda se constata a presenc¸a de alguns problemas tais como o elevado grau de incerteza
na dinaˆmica dos sistemas devido a` inter- e intravariabilidade dos pacientes e a na˜o-linearidades.
Embora tenha sido proposto ate´ hoje um elevado nu´mero de controladores, ainda e´ deseja´vel
alcanc¸ar-se uma melhor soluc¸a˜o. Deste modo uma cont´ınua aposta em estudos nesta a´rea, de
forma a ultrapassar as desvantagens do controlo manual bem como as limitac¸o˜es das estrate´gias
de controlo automa´ticas ja´ desenvolvidas, tem certamente um enorme valor para a comunidade
aneste´sica.
Este trabalho apresenta a implementac¸a˜o de uma estrate´gia de controlo por comutac¸a˜o
baseada em modelos de forma a controlar a resposta de NMB de um paciente sujeito a cirur-
gia geral para um valor de refereˆncia desejado. Modelos de Wiener com uma entrada e uma
sa´ıda, constituidos por um sistema compartimental, que descreve o efeito farmacocine´tico e far-
macodinaˆmico linear, em se´rie com uma na˜o linearidade esta´tica, sa˜o utilizados para modelar a
resposta do NMB a` administrac¸a˜o de dois relaxantes musculares, o atracurium e o rocuronium.
O controlador por comutac¸a˜o e´ constru´ıdo com base num banco de leis de controlo de massa
total, estando cada uma dessas leis sintonizada para um modelo de um banco de modelos desen-
volvido de forma a representar o comportamento da populac¸a˜o. Ale´m disso, e´ apresentada uma
estrate´gia de melhoramento do seguimento de refereˆncia, baseada na ana´lise da resposta NMB
do paciente em estado estaciona´rio.
Palavras-Chave: Controlo Automa´tico do NMB, Modelos Compartimentais, Controlo por
Comutac¸a˜o, Lei de Controlo de Massa, Melhoramento do Seguimento de Refereˆncia.
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Chapter 1
Introduction
1.1 Motivation
Health related research has accomplished major advances in the last decades. In this period the
world has witnessed an exponential development in this area and the tendency is to continue at
a faster scale.
Health care is one of the basic foundations for a good quality of life. So any improvement
in this area is a great social accomplishment. In this context, surgical procedures have a crucial
importance as a way of treating and correcting a very large range of health problems.
Anesthesia is a key factor to the success of a surgery since it provides good conditions for
surgical activity. Therefore, there is a considerable interest in research in this area, leading to
procedures that can assist and simplify the anesthesiologists work as well as for the surgeons.
General anesthesia is achieved by the administration of three types of drugs, a hypnotic, an
analgesic, and a muscle relaxant. Usually, these drugs are manually administered through boluses
given by the anesthesiologists during the surgery. Automatic methods for drug administration
can make this procedure smoother for the patient and lead to less waste of drug.
The present work was carried out within the research project GALENO - Modeling and
control for personalized drug administration (PTDC/SAU-BEB/103667/2008), which aims at
designing personalized drug administration system using modeling, estimation, control and ad-
visory methods.
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1.2 Aims
The automatic control of the neuromuscular blockade (NMB) level (one of the components of
the general anesthesia) can be achieved with a proper positive control law, designed with basis
on compartmental systems models that describe the behavior of the muscle relaxants inside the
body, [Almeida (2010)]. This not only drives the total drug mass in a patient to a desired
reference but also drives the NMB level to a specific target.
The present work is aimed at:
• Presenting a total system mass control law in order to perform the automatic control of
the NMB level in patients with a suitably identified model.
• Developing of a switching strategy to control the NMB level in patients whose model
parameters are unknown.
1.3 Previous Work and State of the Art
Over the past 35 years the development of the tunning of controllers for systems characterized
by the presence of non-linearities and large uncertainties has met some important advances. A
wide range of controllers from a simple on-off controllers [Vries et al. (1986), Wait et al. (1987)]
or PID controllers [Lago et al. (1998)] until intelligent control schemes based on a variety of
theories, like the adaptive, model-based, fuzzy and robust controllers has been achieved amoung
the last years.
Cass et al. (1976) reports one of the first cases of the use of a PID controller (Propor-
tional–Integral–Derivative controller) which the most commonly used is the feedback controller.
This case consisted in the administration of four non-depolarizing muscle relaxants, d-tubocarine,
gallamine, alcuronim and pancuronium to sheep with a pre-defined target of 40% and with an
infusion limited to a maximum of one hour. This led to the conclusion that an automatic control
scheme in order to control the NMB level is achievable in clinical practice. Other authors such
Asbury and Linkens (1986), O’Hara et al. (1991), and Lago et al. (1998), have also developed
work in the area of the PID controllers.
The adaptive model-based closed-loop systems bring a big advance in the control of neu-
romuscular blockade with a wide range of advantages. The development of these models was
possible due to the publication of pharmacokinetic/pharmacodynamic (PK/PD) models, which
are assumed to accurately describe the actual behaviour of NMB agents inside the body. Once
these models were presented, a variety of feedback control schemes designed to lead the NMB
to a desired target have appeared. During the past years authors like Bradlow et al. (1986),
Jaklitsch and Westenskow (1987), Uys et al. (1988), Lendl et al. (1999) and many others have
2
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proposed different feedback schemes in order to present a suitable strategy to control the NMB
level.
Regarding fuzzy logic model based methods, there are many authors that explored this ap-
proach as a simple mean to build a nonlinear controller. Here, Mason et al. (1994), Mason et al.
(1996), Mason et al. (1999), Ross et al. (1997), Edwards et al. (1998), and Shieh et al. (2000)
are some of the many authors that developed this method. Fuzzy logic control consists from a
structural point of view, in a set of rules built via guidelines normally provided by an experi-
enced operator well aware of the proccess under study. Consequently, the controller looks at the
process as a black box and does not need an accurate model description.
The project GALENO - Modeling and control for personalized drug administration (PTDC/
SAU-BEB/103667/2008), a project financed by the FCT - Fundac¸a˜o para a Cieˆncia e a Tec-
nologia, has the objective of designing personalized drug administration systems using modelling,
estimation, control and advisory methods. Over the past years, it has seen several developments
regarding the automatic control of the neuromuscular blockade with the participation of several
researchers which have worked in different ways to pursue the main goal of this project. Adap-
tive control methods were studied in (Lemos et al. (2002a), Lemos et al. (2002b), Lemos et al.
(2003), Lemos et al. (2005a), Lemos et al. (2005b), and Lemos et al. (2006)). These methods
consist in using a parameter dependent controller whose parameters are updated with basis on
the controller system response. PID controllers, switching strategies and observers were studied
in (Magalha˜es et al. (2002a), Magalha˜es et al. (2002b), Magalha˜es et al. (2004), Magalha˜es et al.
(2005), and Magalha˜es (2006)). Observers consist on the modelling of a real system in order to
provide an estimation of its internal state. This modelling is achieved through measurements
of the input and output of the real system. The NMB control with positive total system mass
control laws applied to systems with uncertainties were studied in (Sousa et al. (2007), Sousa
et al. (2008), and Sousa et al. (2010)). Finally, the total system mass control laws applied to
positive systems were studied in (Almeida et al. (2010), Almeida et al. (2011), and Almeida
(2010)). All this developed work allowed a major breakthrough on the automatic control of the
NMB with a reasonable number of techniques already applied in the surgery room that have
shown acceptable results.
1.4 Contributions
Several techniques are applied and tested to perform, both online and oﬄine, the automatic
control of the NMB level.
Regarding online NMB control it was addressed the total system mass control law with
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controller selection based on two techniques. The first one is the switching strategy and the
second one is the Extended Kalman Filter (EKF) used to perform the model identification and
then tuned the corresponding total system control law.
The oﬄine NMB control was also based on the application of the total system mass control
law, but the controller selection was performed with different methods. For controller selection
it was used the controller with the better reference tracking, the controller of the model with the
closest parameters to the ones of the patient model, the controller of the model with the value of
steady-state input (USS) required to achieve a desired reference closest to the one of the patient
model, the controller of the model with the value of Norm 2 closest to the one of the patient
model, the controller of the model with the value of Vinnicombe metric closest to the one of the
patient model, the controller of the model with the closest Impulse Response to the one of the
patient model, and the controller of the model with the closest Step Response to the one of the
patient model.
Comparisons between methods are presented and discussed.
Some work related to the automatic control of NMB level through total system mass control
laws using a switching strategy was published in Teixeira et al. (2012).
1.5 Outline of the Dissertation
Despite all the previous work done in the area of NMB control, some problems related with
the continuous infusion still exist. This is mainly due to a very high degree of uncertainty in
the system dynamics caused by the intra- and intervariability in the patients, noise level, sensor
faults, nonlinearities, time variations and control actions constrains. Although a large range of
control strategies have been proposed and studied, a suitable and acceptable anesthetic solution
has not yet been achieved. So research developments that allow to overcome the drawbacks of
the manual control as well as the limitations of the past NMB control strategies have a high
impact in the anesthetic community.
Chapter 2 presents an overview of anesthesia. Here the existence of a large range of anes-
thetic solutions is emphasized and the particular case of the general anesthesia will be further
studied once it is the type of anaesthesia addressed in this work. The different general anesthesia
components as well as the drugs used to achieve it will be presented. Moreover an explanation
is given about the importance of anesthetic procedures during surgeries, as well as, about the
induction and maintenance of anesthesia. In a second part of chapter the particular case of Neu-
romuscular Blockade (NMB) was studied, with a focus in the anatomy and physiology related
with the NMB process, which means to explain how the muscle relaxants work over the muscle
paralysis. Furthermore a brief description of the main muscle relaxants addressed in this work
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is made.
In chapter 3 all the theoretical ground of the work is presented. Here two compartmental
models are introduced, firstly the main PK/PD compartmental model is addressed and secondly
a new compartmental model, known as reduced parameter compartmental model is presented.
These models describe the relation between the quantity (or concentration) of administered
drug and the quantity (or concentration) of drug which is actually effective. After that the Hill
Equation adapted to each compartmental model, is introduced. This is a nonlinear equation that
relates the drug effect concentration with its effect, i.e., with the NMB level of the patient. The
total system mass control law is presented and studied in order to show that leading the total
system mass to a reference value the NMB level is also drived to a specific desired target. Also
the open-loop control technique TCI is briefly described. After that a switching strategy between
total system mass control laws is introduced. The switching strategy is explained together with
the switching criterion. Then some results of NMB control with switching strategy are presented,
and a study comparing the switching strategy and the Extended Kalman Filter (EKF) strategy is
performed, as well as a comparative study with several oﬄine controllers chosen based on different
metrics. Finally a strategy to improve the reference tracking quality is presented together with
the results obtained after its application.
Chapter 4 is devoted to the clinical environment, i.e., to all the practical work developed on
the application of the NMB control on real patients during surgery ranging from the hardware
to the software used for the work, the protocol applied by the anesthesiologists as well as the
outcomes obtained.
Finally, Chapter 5 contains the conclusions of the developed work as well as some suggestions
for future work.
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Chapter 2
Anesthesia
In surgical procedures where the absence of pain, feeling/sensation and/or movement is essential,
anesthesia is an important aspect to consider. There are four main types of anesthesia:
• Local : numbs one small area of the body. The patient stays awake and alert;
• Conscious sedation: uses a mild sedative to relax the patient and pain medicine to relieve
pain. The patient stays awake but may not remember the procedure afterwards;
• Regional anesthesia: blocks pain in an area of the body, such an arm or leg. Epidural
anesthesia is a type of regional anesthesia;
• General anesthesia: affects the whole body. The patient goes to sleep and feels nothing,
and should have no memory of the procedure afterwards.
For the purpose of this work only the general anesthesia will be assessed.
2.1 General Anesthesia
2.1.1 General Anesthesia
General anesthesia enables a patient to tolerate surgical procedures that would otherwise inflict
unbearable pain, potentiate extreme physiologic exacerbations, and result in unpleasant memo-
ries. General anesthesia uses intravenous and inhaled agents to allow adequate surgical access
to the operative site. Anesthesiologists are responsible for assessing all factors that influence a
patient’s medical condition and for selecting the optimal anesthetic technique accordingly.
The main features of general anesthesia are the following::
• It allows proper muscle relaxation for prolonged periods of time;
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• It can be administered rapidly and is reversible;
• It reduces intraoperative patient awareness and recall;
• It can be adapted easily to procedures of unpredictable duration or extent;
• It facilitates control of the airway, breathing, and circulation.
2.1.2 General Anesthesia Components
General anesthesia can be defined as a reversible state of unconsciousness where three variables
must be controlled: hypnosis, analgesia, and areflexia. For this purpose, the anesthesiologists
need to administrate three different types of drugs: hypnotics, opioids and muscle relaxants.
Hypnotic drugs are a class of psychoactives whose primary function is to produce uncon-
sciousness and sedation in surgical anesthesia. Examples of hypnotics are isoflurane, sevoflurane
and desflurane (volatile drugs), and propofol (intravenous drug).
Opioid (or analgesic) are drugs used to relieve pain and to achieve analgesia. The analgesic
effects of opioids are due to decreased perception of pain, decreased reaction to pain as well as
increased pain tolerance once they act in the opioid receptors, from the central and peripheral
nervous system. Examples of analgesics are fentanil, sufentanil and remifentanil (all intravenous
drugs).
Finally, areflexia is defined as the lack of movement produced by muscle relaxants, or neuro-
muscular blockade agents (NMBA) [Esteves (2008)]. This drugs affect skeletal muscle function
and decrease the muscle tonus by blocking nerve impulses so that muscles cannot contract,
creating paralysis, a desired condition to facilitate tracheal intubation and to maintain good sur-
gical conditions. Examples of muscle relaxants are succinylcholine, atracurium, cis-atracurium,
vecuronium and rocuronium (all intravenous drugs).
The administration of a particular hypnotic, analgesic or muscle relaxant during a surgical
procedure is a choice of the anesthesiologist, where patient characteristics, hospital protocols and
the type of surgery are aspects to take into account.
2.1.3 Manipulation of the General Anesthesia Components
In order to manipulate the drug input the anesthesiologist has to supervise some physiological
signals from the patient, so that he knows when and how to act in order to preserve a good level
of anesthesia. It is based on the interpretation of specific patient signals that the anesthesiologist
makes the decision of increase, decrease or cease the drug input.
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In order to manipulate the depth of anesthesia (DoA) the anesthesiologist uses information
from several physiological signals and depending on the stage of the surgery decides the anesthetic
protocol, i.e., the amount of hypnotic and analgesic to deliver. However it was need to take into
account that the analgesic drugs only affect the DoA if used in large amounts, which does not
usually occur.
Nowadays, BIS signal (Bispectral index, which is a measure of the level of consciousness) is
widely used in surgery rooms and it is accepted as a measure of the DoA: if the BIS signal is
to high the anesthesiologist knows he needs to increase the drug input, and if it presents too
low values he knows that he needs to decrease the drug input (Note that the BIS signal must
be preserved between 40 and 60%). Fig. 2.1 illustrates the BIS sensor and its way to use and
Fig. 2.2 the main BIS monitor. Nevertheless, this signal presents some drawbacks namely the
noise from the surgical instruments and electromyography that affect the quality of the signal.
Therefore, signals such the BIS-SQI signal, quality index of the BIS, and theBIS-EMG signal,
interference of the electromyographic signal into the BIS signal, are used. In the first one, if the
value is too low the anesthesiologist ignores the correspondent BIS value and waits for further
values with better BIS-SQI to validate any action. In the second one, if the value is high the
anesthesiologist ignores the BIS values, and if the value is low it means a clean BIS signal that
can be used to make a decision. Finally signals like the heart rate and the blood pressure are
supervised to restrain the increase of input of the hypnotic and the analgesic.
Figure 2.1: BIS Sensor.
In summary, the anesthesiologist uses the BIS signal as a measure for the hypnotic, which
influences directly the DoA, but also the analgesic, which interacts with the hypnotic drug in
the DoA. Signals like the BIS-SQI and BIS-EMG are used to validate the BIS signal, and heart
rate and blood pressure are used to supervise the hypnotic and analgesic administration.
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Figure 2.2: BIS Signal.
As for arreflexia, its manipulation is much easier and direct than the one of the depth of
anaesthesia [da Silva et al. (2010), da Silva et al. (2012), Esteves (2008)]. Here the anesthesiologist
only has to use the TOF signal (Train-Of-Four), which is used to measure the level of NMB.
This signal is the patient’s response to an evoked EMG obtained at the hand of the patient by
a sequence of four external stimulations of the ulnar nerve (Fig. 2.3). A baseline measurement
is done before paralytic agent is administered in order to determine the current necessary to
obtain twitch. The signal (Fig. 2.3) is graphically represented by four bars, which correspond
to the four twitches. At the beginning those bars are full (full muscle capacity) and when the
muscle relaxant is administered the values decrease and come to zero by full paralysis. The value
used to control the muscle relaxant input is T1, the first twitch of the TOF signal. If T1 is too
high the anesthesiologist knows that more muscle relaxant is needed in order to increase muscle
paralysis. Another value used, but in order to reverse the muscle paralysis is the TOF Ratio,
given as the quotient between T4, the four twitch of the TOF signal, and T1. This value allows
the anesthesiologist to know if he can apply the muscle relaxant reverser. If the TOF Ratio is
different from 0 he knows that the reverser can be administered.
In summary, the anesthesiologist uses the TOF signal to handle the input of the NMB agents,
using the T1 to manipulate the muscle paralysis agent and the TOF Ratio to identify when the
reverser can be administered.
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Figure 2.3: Mechanotransducer in the left image and TOF signal in the right image.
The values of the signals BIS, BIS-SQI, BIS-EMG, T1, T2, T3, T4, and TOF Ratio range from
0 to 100.
2.2 Neuromuscular Blockade (NMB)
2.2.1 NMB Anatomy and Physiology
The normal neuromuscular junction (NMJ) consists of a presynaptic neuron, a Schwann cell
(covering the neuron), and a postsynaptic muscle fiber [Guyton and Hall (2000)]. The presynap-
tic neuron stores and releases Acetylcholine (ACh). ACh receptors exist at both junctional and
extrajunctional areas of muscle fibers. When a nerve impulse reaches the end of a presynaptic
neuron, N-type Ca++ channels increase the intracellular calcium concentration, which causes the
synaptic vesicles to release ACh into the endplate. These ACh molecules then bind to the junc-
tional receptors allowing for Na+ and Ca++ influx into the muscle cell, which ultimately leads
to contraction due to the end plate potential. Aceytlcholinesterases quickly degrade available
synaptic ACh, preventing prolonged contraction [Appiah-Ankam and Hunter (2004)].
A decrease in the binding of acetylcholine leads to a decrease in its effect and neuron trans-
mission to the muscle is less likely to occur [Appiah-Ankam and Hunter (2004)]. There are two
types of drugs that affect the transmission at the neuromuscular junction: depolarizing and non-
depolarizing. Depolarizing drugs, such as succinylcholine, have the same effect on the muscle
fibre as does acetylcholine. The difference between these drugs and acetylcholine is that they are
not metabolized by acetylcholinesterase so a prolonged activation of the acetylcholine receptors
is produced (depolarization of the motor end plate). Non-depolarizing drugs, such as atracurium
and rocuronium block the action of acetylcholine on the acetylcholine receptor sites and therefore
no end plate potential is developed [Appiah-Ankam and Hunter (2004)].
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Figure 2.4: Neuromuscular junction [Magalha˜es (2006)].
The infusion of muscle relaxant drugs is frequent during the surgery for three reasons:
• To eliminate spontaneous breathing and promote mechanical ventilation (e.g. to eliminate
the urge to fight the vent);
• To cause a pharmacological restraint so patients do not harm themselves;
• To decrease oxygen consumption.
Neuromuscular blockade agents (NMBA) are non-depolarizing drugs that block the neuro-
muscular transmission and consequently lead to muscle paralysis. Besides the already mentioned
drugs atracurium and rocuronium, examples of such agents are cis-atracurium and vecuronium
[Appiah-Ankam and Hunter (2004)].
After an infusion of an initial bolus of NMBA to facilitate tracheal intubation, the maintenance
of muscle relaxation for long periods of time during surgery can be achieved by two different ways,
namely it may be ensured either by continuous infusion or by further increments (top-ups) of
NMBA at regular instants of time.
A bolus is a single dose B of drug usually injected into a blood vessel over a short period of
time. It can be mathematically represented by:
u(t) = Bδ(t) [µg/kg], (2.1)
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where δ(t) is the Dirac δ function. On the other side, the continuous infusion of a quantity ki of
drug in a time interval [ti, ti+1] may be represented by the following step function:
u(t) = ki [µg.kg
−1.min−1], ti ≤ t ≤ ti+1, i = 0, 1, 2, 3, . . . . (2.2)
For the purpose of this work atracurium and rocuronium will be the NMBA’s under consid-
eration.
2.2.2 Atracurium
Figure 2.5: Atracurium molecular structure.
Atracurium is a benzyl isoquinolonium ester and can be defined as an intermediate-duration,
short-acting relaxant in the category of non-depolarizing neuromuscular blocking drugs, used
adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle re-
laxation during surgery or mechanical ventilation. An initial atracurium dose of 0.4 to 0.5 mg/kg
provides a maximum neuromuscular blockade within 3 to 5 minutes of injection, and a recovery
occurs approximately between 20 to 35 minutes after injection. The neuromuscular blocking
action of atracurium is enhanced in the presence of potent inhalation anesthetics like isoflurane
and enflurane which increase the potency of atracurium and prolong neuromuscular block by
approximately 35%. The onset time decreases and the duration of maximum effect increases with
the increase of the dose. Atracurium is rapidly broken down by the body to inactive metabolites
by ester hydrolysis (minor pathway) and spontaneous Hoffman degradation (major pathway).
The reversion of the neuromuscular blockade can be achieved with an anticholinesterase agent
such as neostigmine in conjunction with an anticholinergic agent such as atropine. Reversal can
usually be attempted when recovery of muscle twitch has started. Complete reversal is usually
attained within 8 to 10 minutes of the administration of reversing agents.
Schematically, atracurium can be characterized as follows:
• Structure: Benzyl isoquinolinium compound;
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• Dosing : 0.4-0.5 mg/kg with onset in 3-5 minutes, lasting 20-35 minutes;
• Metabolism: Cleared by non-enzymatic degradation (Hofmann elimination) as well as ester
hydrolysis by plasma esterases.
2.2.3 Rocuronium
Figure 2.6: Rocuronium molecular structure.
Rocuronium is an aminosteroid non-depolarizing muscle relaxant used in modern anesthesia,
to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or
mechanical ventilation. As a non-depolarizing drug, rocuronium binds competitively to cholin-
ergic receptors on motor end-plate to antagonize action of acetylcholine, resulting in a blockade
of neuromuscular transmission. An initial rocuronium dose of 0.6 mg/kg provide a maximum
neuromuscular blockade within 1 to 2 minutes of injection, and a recovery occurs approximately
between 20 to 35 minutes after injection. The neuromuscular blocking action of this drug is en-
hanced in the presence of inhalation anesthetics like sevoflurane, isoflurane, and enflurane. The
onset time decreases and the duration of maximum effect increases with the increase of the dose.
Rocuronium is mostly cleared in the bile (essentially unchanged) (major pathway) although up
to 30% may be excreted renally (minor pathway). Note that individual responses to this drug
are highly variable, and the duration of the effect is difficult to predict. The main advantage of
using rocuronium instead of atracurium is the existence of sugammadex, a reversal of neuromus-
cular blockade without relying on inhibition of acetylcholinesterase, like neostigmine. Also the
reversion can be realized at any point, and so it is not necessary to expect the initial recovery
from the initial bolus. The reversion of the neuromuscular blockade can also be achieved with an
anticholinesterase agent such as neostigmine in conjunction with an anticholinergic agent such
as atropine, but reversal can only be attempted when recovery of muscle twitch has started. In
comparison with atracurium, rocuronium has a lower potency and so a higher dose is required
for the same effect, leading to a higher concentration gradient and a faster onset.
Schematically, rocuronium is characterized as follows:
• Structure: Aminosteroid compound;
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• Dosing : 0.6 mg/kg onset in 1-2 minutes and lasts 20-35 minutes;
• Metabolism: Rocuronium is mostly cleared in the bile (essentially unchanged) although up
to 30% may be excreted renally. Note that individual responses to rocuronium are highly
variable, and the duration of the effect is difficult to predict.
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Chapter 3
Automatic Control
The manual control is tedious, slower and more prone to errors. Thus, the development of pro-
cedures for automatic control is of great interest, once they allow a more rigorous determination
of the drug infusion dose and decrease the tendency to error.
Figure 3.1: Elementary NMB control scheme.
To achieve an efficient automatic control, the effect of drug on the NMB of a patient needs
to be modelled by means of mathematical equations.
3.1 Drug Effect Models
In order to model the effect of a drug, pharmacologists often separate their analysis into two
steps. First, they built a pharmacokinetic (PK ) model that relates the administered drug dose
with the blood drug concentration. In a second stage, a pharmacodynamic (PD) model is
derived, describing the relation between the former concentration and the drug concentration in
the relevant part of the body, known as the effect concentration, as well as the relation between
the effect concentration and the actual drug effect (here the NMB level).
3.1.1 Drug Dose/Effect Concentration Models
The most common models for the effect concentration of a drug are compartmental systems.
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A system is a set of interconnected elements that are dependent on each other and form a
unit that has specific characteristics and functions [Magalha˜es (2006), Marques (2008)]. Each
system admits states that are defined as a set of variables capable to describe the system in any
instant of time. Systems can be classified as continuous or discrete-time systems according to
the continuous or discrete nature of the time-line over which their variables are defined. Also,
systems can be classified as open, closed or isolated. An open system can exchange matter or
energy with its surroundings, while a closed system can only exchange energy, but not matter
with its surroundings. In contrast, an isolated system cannot exchange neither energy nor matter.
Compartmental systems are widely used to model the pharmacodynamics and pharmacoki-
netics of intravenously administered drugs [Godfrey (1983), Hof (1996), Beck et al. (2007)]. A
compartmental system is a system that has a finite number of homogeneous, well-mixed sub-
systems, called compartments that exchange material among them and with the environment.
These models are based on the principle of mass conservation.
Figure 3.2: Representation of a compartment.
Fig. 3.2 represents a compartment, in this case compartment i; here bi represents the input
rate (the drug infusion rate to a patient if we consider the specific case of anesthesia), xi is
the concentration of material in the compartment i, kij represents the rate of mass transfer
from compartment i to compartment j, and ki0 represents the rate of material output from
compartment i to the environment.
The input to compartment i, is given by bi.u, where u is the total system input. This input,
the state xi and all the rate constants are assumed to be non-negative.
At each time instant t, the variation x˙(t) in the concentration of material in compartment i
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is then given by [Marques (2008), Almeida (2010)]:
x˙i(t) = −
n∑
j=0,
j 6=i
kijxi(t) +
n∑
j=1,
j 6=i
kjixj(t) + biu i = 1, . . . , n. (3.1)
where n is the total number of compartments.
Assuming that a linear combination of the concentrations of material in each compartment
is the relevant system feature, the output of the system is defined as:
y(t) = c1x1(t) + . . .+ cnxn(t). (3.2)
It is assumed that the ci are non-negative and that at least one of them is strictly positive.
Gathering in a vector all the concentrations xi of material in the different compartments, i.e.,
defining
x(t) =

x1(t)
...
xn(t)
 ,
the previous equations can be written in matrix form as:
 x˙(t) = Ax(t) +Bu(t)y(t) = Cx(t) t ≥ 0, (3.3)
where
B =

b1
...
bn
 ,
is a n× 1 (column) and C =
[
c1, . . . , cn
]
, is a 1× n matriz (row), and A is a matrix n× n of
the form:
A = (aij),
with:
aii = −
n∑
j=0
j 6=1
kij
aij = kji (i 6= j).
(3.4)
Models as the one given by equations (3.3) are known as linear state-space models.
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The vector x(t) is known as the state vector, as it collects all the necessary information about
the system at time instant t in order to describe its future behaviour, under the influence of a
given input u.
Due to the fact that matrix A is of the form (3.4) and that B and C have nonnegative
components and that at least one of its components is strictly positive, it turns out that when the
initial state and the input are nonnegative, then the states and the output remain nonnegative.
The particular features of the matrix A are that:
• It is a Metzler Matrix, i.e., all off-diagonal values are non-negative:
aij ≥ 0, ∀i, j with i 6= j
• All its diagonal values are non-positive:
aii ≤ 0, ∀i
• It is a diagonally dominant matrix, i.e.,
| aii |≥
∑
j 6=i
aij ∀i.
A matrix with these properties is called a compartmental matrix.
In the sequel, two types of compartmental models are introduced in order to describe the
administration of NMBA, namely the PK/PD compartmental model and the reduced parameter
model. These will be used as basis for the implementation of automatic control procedures.
PK/PD Compartmental Model
In this specific work, a mammillary model is considered to represent the pharmacokinetics
and pharmacodynamics of NMBA infusion (Fig. 3.3) [Magalha˜es (2006), Beck et al. (2007),
Almeida (2010)]. A mammillary model is a compartmental model in which a central compartment
is surrounded by p-1 peripheral compartments which exchange matter only with the central
compartmental and not with one another. Pharmacokinetics describes the path that a drug
does inside the body, whereas pharmacodynamics means the pharmacology field that studies the
physiological effects of drugs, and their mechanisms of action.
Here this model includes three compartments, where two of them represent the pharma-
cokinetic model (C1 and C2), combined with an effect compartment (Ce) which is part of the
pharmacodynamic part of the model, see Fig. 3.3.
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Figure 3.3: Block diagram of the mammillary PK/PD compartmental model.
The corresponding state-space equations are as follows.

x˙1
x˙2
x˙3

︸ ︷︷ ︸
x˙
(t) =

−(k12 + k10 + k1e) k21 0
k12 −(k21 + k20) 0
k1e 0 −ke0

︸ ︷︷ ︸
A
.

x1
x2
x3

︸ ︷︷ ︸
x
(t) +

1
0
0

︸ ︷︷ ︸
B
u(t)
y(t) =
[
0 0 1
]
︸ ︷︷ ︸
C
.

x1
x2
x3

︸ ︷︷ ︸
x
(t). (3.5)
This model has six patient dependent parameters, k10, k12, k1e, k20, k21, and ke0 (min
−1)
that must be identified for each particular patient. The state variables x1 and x2 (µg/kg)
correspond to the drug concentrations in compartments C1 and C2, whereas x3 (µg/kg) is the
drug concentration in the effect compartment, also known as effect concentration. The input u(t)
(µg/kg/min) corresponds to the delivery rate of drug concentration with respect to the central
compartment, and is computed as u(t) = u˜(t)/V1, where u˜(t) is the drug delivery rate, and V1
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is the volume of the central compartment. The output y(t) (µg/kg) corresponds to the effect
concentration.
Reduced Parameter Compartmental Model
The reduced parameter model described in da Silva et al. (2012) has been derived by system
identification techniques, rather than by pharmacological considerations. It can be described
as a compartmental system as seen in Fig. 3.4. Although it is equally a mammillary tri-
compartmental model, with two compartments representing the pharmacokinetic model (C1
and C2), combined with an effect compartment (C3) which represents the pharmacodynamic
model, the rate exchange constants are not the same as in the previous model. This leads to a
different system, with different state-space equations. More concretely the model equations are
the following [da Silva et al. (2012), Almeida (2010)].
Figure 3.4: Block diagram of the mammillary reduced parameter compartmental model.

x˙1
x˙2
x˙3

︸ ︷︷ ︸
x˙
(t) =

−k3α 0 0
k2α −k2α 0
0 k1α −k1α

︸ ︷︷ ︸
A
.

x1
x2
x3

︸ ︷︷ ︸
x
(t) +

k3α
0
0

︸ ︷︷ ︸
B
u(t)
y(t) =
[
0 0 1
]
︸ ︷︷ ︸
C
.

x1
x2
x3

︸ ︷︷ ︸
x
(t). (3.6)
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This model has four parameters, k1, k2, k3 (min
−1) and α (alpha) (dimensionless) that, as
in the previous case, must be identified for each particular patient. However good results are
obtained if the parameters k1, k2, k3 are fixed, based on previous knowledge on the patient pop-
ulation, and only α is identified for each particular patient. This constitutes a great advantage.
The values of k1, k2 and k3 used in the sequel are k1 = 1, k2 = 4 and k3 = 10, [da Silva (2011)].
The state variables x1 and x2 (µg/kg) correspond to the drug concentrations in compartments
1 and compartment 2, whereas x3 (µg/kg) is the drug concentration in the compartment 3, also
known as effect concentration. The input u(t) (µg/kg/min) corresponds to the drug delivery
rate with respect to the central compartment, and is computed as u(t) = u˜(t)/V1, where u˜(t)
is the drug delivery rate, and V1 is the volume of the central compartment. The output y(t)
(µg/kg) corresponds to the effect concentration.
3.1.2 Effect Concentration/ Drug Effect Models
As an output from the models presented in the previous subsection, the effect concentration,
y(t), is obtained. The effect concentration corresponds to the percentage of administered drug
that will produce effect in the NMB level, r(t).
The relationship between the effect concentration and the NMB level is given by the Hill
Equation; this is a nonlinear static equation, which assumes slightly different forms for the
PK/PD model and for the reduced parameter model.
For the PK/PD model [Beck et al. (2007)]:
r(t) =
100
1 +
(
y(t)
C50
)γ , (3.7)
where C50 (µg/kg) and γ (dimensionless) are patient-dependent parameters.
For the reduced parameter model [Almeida (2010)]:
r(t) =
100
1 +
(
y(t)
k.C50
)γ , (3.8)
where C50 (µg/kg) is a fixed parameter equal to 0.6487 for atracurium and 1/5 for rocuronium,
γ (dimensionless) is patient-dependent parameter and k = 5 (dimensionless) [Almeida (2010)].
The responses of the PK/PD model and of the reduced parameter model to a drug bolus are
illustrated in Fig. 3.5. As can be seen, the behavior of the reduced parameter models differs from
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Figure 3.5: Simulation of 100 atracurium PK/PD models (blue lines) and 100 atracurium re-
duced parameter models (red lines) to a bolus of 500µg/kg during 100 minutes. The upper plot
represents the first 10 minutes, and the lower plot represents the remaining time.
the one of the PK/PD models mainly in the transient stage.
3.2 NMB Control Law
In this section two strategies are used in order to control NMB to a desired level. The first one
is an open-loop strategy, whereas the second one is based on a closed-loop control law.
3.2.1 Open-Loop Control - TCI
An open-loop controller, also called a non-feedback controller, is a type of controller which
computes its input into a system using only a model of the system and the knowledge of the
desired control objective.
Open-loop control is useful for well-defined systems where the relationship between input and
the resultant state or output can be modelled by a mathematical formula. Such control does
not use the comparison between the obtained output and the desired one in order to autocorrect
itself. This means that the control variable input does not depend on the observation of the
output of the processes under control.
TCI control (Target Controlled Infusion) for neuromuscular blockade level is an example of
an open-loop control [Bressan et al. (2010)], where the input is stationary, i.e. u(t) ≡ uref , t ≥ 0.
The adequate value of uref is computed as follows. Given a desired reference value rref for the
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NMB level, invert the Hill Equation in order to obtain the corresponding reference value yref for
the effect concentration. Due to the characteristics of the compartmental systems that model
the drug dose/effect concentration relationship, it turns out that these models have stationary
solution x(t) ≡ xref , u(t) ≡ uref and y ≡ yref . More concretely xref = −A−1.B.uref and uref =
−(C.A−1.B)−1.yref . The TCI control strategy consists in taking the drug dose constantly equal
to uref . Since the patient’s initial state is null, and not equal to xref , the effect concentration is
not immediately equal to yref , implying that the NMB level r(t) does not immediately coincide
with the desired value rref . However, r(t) tends to rref as time evolves.
3.2.2 Closed-Loop Control - Total Sistem Mass Control Law
In this section it is first shown that it is possible to stabilize the “total mass” of a compartmental
system (M) at a given set-point M∗ > 0 using a suitable feedback control law presented in
[Bastin and Provost (2002)].
The total mass of a compartmental system with n compartments is defined as [Marques
(2008), Sousa et al. (2010)]:
M (x(t)) =
n∑
i=1
xi. (3.9)
Note that the states of the compartmental models used in this work do not correspond to
drug masses, but rather to drug concentrations. Therefore their sum cannot be interpreted as a
mass. However the terminology ”total mass” is used in order to keep in line with the literature
on this subject.
The objective is to track a constant reference yref by leading the system to an equilibrium
point Xe = [xe1 x
e
2 x
e
3]
T
where xe3 = yref . This is achieved by leading the system mass to an
adequate value M∗.
For the PK/PD model M∗ is given by:
M∗ = (α1 + α2 + 1)yref , (3.10)
where
α1 =
ke0
k1e
,
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α2 =
k12ke0
k1e(k21 + k20)
,
as shown in [Magalha˜es, 2006].
For the reduced parameter model:
M∗ = 3.yref , (3.11)
[Almeida, 2010], meaning that the total mass is equally distributed by the three compartments.
The control law is of the form:
u˜(t) = u˜(x(t)) = Kx(t) + L, (3.12)
where the 1× 3 matrix K and the real number L must be suitably chosen.
Since a compartmental system admits only positive values as inputs, the control law should
provide only such type of values. Therefore, once a theoretical feedback control law u˜(t) is
defined, the input value to be applied is given by:
u(t) = max(0, u˜(t)). (3.13)
The choice of K and L is made based on the following considerations.
Let x˙(t) = Ax(t)+Bu(t) be a compartmental system. Its total mass corresponding to a state
x can be written as M(x) = [1 · · · 1]x. Then:
[1 · · · 1]x˙(t) = [1 · · · 1]Ax(t) + [1 · · · 1]Bu(t), (3.14)
which is equivalent to
˙̂
M(x(t)) = [1 · · · 1]Ax(t) + (Σbi)u(t), (3.15)
Once the convergence of total mass to the value M∗ is desired, the idea is, if possible, to
determine u(t) in such way that (3.15) takes the form:
˙̂
M(x(t)) = −λ (M(x(t))−M∗) , (3.16)
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where λ is a positive value. Since
˙̂
M∗ = 0 because M∗ is a constant, this i.e.:
˙̂
M(x(t))−M∗ = ˙̂M(x(t)) = −λ (M(x(t))−M∗) . (3.17)
In this way, defining:
∆M(t) = M(x(t))−M∗, (3.18)
it holds that
˙̂
∆M = −λ∆M(t), (3.19)
and hence:
M(x(t))−M∗ = ∆M(t) = e−λt∆M(0) −→
t→∞ 0, (3.20)
meaning that:
M(x(t)) −→
t→∞M
∗. (3.21)
as desired.
Equating the right-hand sides of (3.15) and (3.16) and solving in order to u(t), yields:
[1 · · · 1]Ax(t) + (Σbi)u(t) = −λ(M(x(t))−M∗)
⇔ u(t) = (Σbi)−1 [−λ(M(x(t))−M∗)− [1 · · · 1]Ax(t)]
⇔ u(t) = (Σbi)−1 [−λM(x(t)) + λM∗ − [1 · · · 1]Ax(t)]
⇔ u(t) = (Σbi)−1 [−λ[1 · · · 1]x(t) + λM∗ − [1 · · · 1]Ax(t)]
⇔ u(t) = (Σbi)−1 [[1 · · · 1](−λI −A)x(t) + λM∗] .
(3.22)
This shows that the control law:
u(t) = u(x(t)) = (Σbi)
−1 [[1 · · · 1](−λI −A)x(t) + λM∗] , (3.23)
allows the mass stabilization of a compartmental system around a set-point M∗.
27
CHAPTER 3. AUTOMATIC CONTROL
The previous equation (3.23) can be rewritten as:
u(t) = u(x(t)) = (Σbi)
−1[1 · · · 1](−λI −A)︸ ︷︷ ︸
K
x(t) + (Σbi)
−1λM∗︸ ︷︷ ︸
L
, (3.24)
as in (3.12).
Finally it is shown in Magalha˜es (2006), Sousa et al. (2007) and Almeida (2010) that taking
u(t) = max(0, u˜(t)), with u˜(t) given by (3.12), not only leads the total system mass M(x(t)) =
3∑
i=1
xi(t) to a value M
∗, but also leads the effect concentration, y(t), to a value y∗ (3.10) (3.11).
This can be used to control the NMB level in the following way. Given a desired reference value
rref = r
∗ for the NMB, compute the corresponding reference level for the effect concentration
y∗ by inverting the Hill equation, i.e.
y∗ =
(
100
r∗
− 1
)1/γ
× C50, (3.25)
for the PK/PD model.
y∗ =
(
100
r∗
− 1
)1/γ
× k.C50, (3.26)
for the reduced parameter model.
Then obtain M∗ as in (3.10) or (3.11), according to the model that is used. Finally, use
this value of M∗ in the control law (3.24). This guarantees that the NMB follows the desired
reference level, r∗.
Note however that this control strategy strongly rests on knowledge of the patient-dependent
parameter γ, which is unknown in practical cases. Moreover, for the PK/PD model it also
depends on the parameters k12, k1e, k20, k21, ke0, and C50. In order to overcome this situation,
a switching control strategy is introduced in the next section.
3.3 NMB Control Strategy
Due to the very high degree of uncertainty in the system dynamics and to the intra- and inter-
variability in the patients, multiple models have emerged over the past years as an alternative
to the PID, adaptive, fuzzy and robust controls in order to overcome those problems.
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The study of multiple model switching control is not new. Authors like Morse (1996), Morse
(1997), Narendra and Balakrishnan (1994), Narendra and Balakrishnan (1997) and others have
studied this over the past years.
Over the next sections this control scheme will be approached. The strategy corresponding
to this scheme will be addressed together with the selection criterion to perform the switching
during the NMB control. Finally an improvement to the reference tracking will be proposed in
order to overcome some issues with the switching control strategy.
It is important to note that for this work only the reduced parameter models will be addressed.
As has been seen during this chapter the PK/PD models differ from the reduced parameter
models in the number of patient-dependent parameters: the former models have eight patient-
dependent parameters and the latter ones have only two. This implies much more variability in
the PK/PD models and much more uncertainty in the NMB control since more parameters have
to be identified in order to perform the total system control mass law (3.24).
3.3.1 Switching Strategy
The requirements of a good controller are speed, accuracy and stability relative to the target.
Achieving these features in complex systems, in the presence of large uncertainty in the process
to be controlled is not always possible with classical adaptive controllers, and therefore switching
control appears in order to overcome the problems faced by previous controllers.
Multiple model switching control [Morse (1996), Morse (1997), Narendra and Balakrishnan
(1994), Narendra and Balakrishnan (1997), Neves et al. (2000), Neves (2003), Magalha˜es (2006)]
uses a bank P of possible models for the process in order to obtain a bank K of controllers each
of them tuned for a specific model. At each time instant a controller is chosen to be active. The
controller selection criterion is based on a pre-specified measure of proximity between the process
and the model for which the controller is tuned. The outcome of this proximity measure usually
varies in time, leading to the switching from one controller to another.
Since atracurium and rocuronium are the two main NMBA used during surgeries, these were
the drugs considered for the purpose of this work.
Therefore a bank P = {P1, . . . ,PN} of representative reduced parameter models is considered,
together with a bank of the corresponding total system mass controllers K = {K1, . . . ,KN} each
of them tuned according to what has been explained in section 3.2.2.
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Figure 3.6: Basic scheme of a switching controller for a process P: K1...KN are the controllers
in the bank K, and S is the controller selection procedure.
More concretely if Pi = P(αi, γi) then Ki produces the control law:
ui(t) = max(0, u˜i(t)),
with
u˜i(t) = (Σbi)
−1[1 · · · 1](−λI −Ai)x(t) + (Σbi)−1λM∗i , (3.27)
For the action of atracurium the bank P was built taking into account real data acquired
during surgeries. Based on that data the joint distribution for the parameters (α, γ) is considered
as follows [Rocha et al. (2011)]:
(ln(α), ln(γ)) ∼ BN(µ,Σ), (3.28)
where
µ =
 −3.2870
0.9812

is the mean vector and
Σ =
 0.0250 −0.0179
−0.0179 0.1196

is the covariance matrix.
The standard bank of representative models, consisting of a linear part (compartmental model)
plus a nonlinear part, the (Hill Equation), was generated from this distribution (See Appendix
C.1).
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Figure 3.7: Red: real NMB responses acquired during surgery performed with atracurium. Blue:
NMB responses of the atracurium models from the bank P. In both NMB responses an initial
bolus of 500µg/kg was administered.
A similar study of the action of rocuronium is still being performed, and at this point only
a set of real data acquired during 41 surgeries is available. For each of these real cases, the
parameters α and γ were identified, and the corresponding models were taken as the standard
bank of models to perform switching control.
Note that for this work only 37 models of the original 41 will be used since four models were
eliminated due to unsatisfactory results for the NMB control via switching (See Appendix C.2).
After the controller bank K is obtained, the switching strategy only needs a switching criterion
in order to select the controller that should be made active to achieve a better reference tracking.
3.3.2 Switching Criterion
In order to perform switching among the controllers Ki contained in the bank K previously
mentioned, it is necessary to establish a criterion so that the system ”knows” when a switching
is advisable.
It is important to notice that due to clinical constraints the automatic control of the NMB
does not start immediately after the beginning of the surgery, but only after the recovery from an
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initial bolus, t∗ (the time instant t∗ is detected automatically by the OLARD algorithm introduced
in [da Silva et al. (2009)]). And so, from that moment forward the switching controller computes
at each instant the ”nearest model” to the patient and applies the control input corresponding
to the associated controller to the patient (See Fig. 3.8).
Figure 3.8: Switching control scheme.
The procedure to choose a controller (represented by the box Controller Choice Fig. 3.8) has
as main goal to select the model that minimizes the following function of the error identification:
ej = rpatient − rj
where rpatient is the patient’s NMB response and the rj is the NMB response of the model Pj ,
j ⊂ 1, . . . , N . More concretely, proximity is here measured by the cumulative quadratic error.
The controller to be selected is the one corresponding to the following minimizing model:
fj(k) =
k∑
l=t∗
|ej(l)|2. (3.29)
In order to initialize the procedure at the instant time t = t∗ (that corresponds to the recovery
from the initial bolus) a random controller from bank K is chosen.
The process of switching control can thus be summarized as:
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• Step 1 t = 0: An initial bolus is given to the patient.
• Step 2 0 < t < t∗ (before recovery from the initial bolus): The control input remains zero.
• Step 3 t = t∗ (t∗ computed by the OLARD algorithm introduced in da Silva et al. (2009)):
A random controller from bankK is chosen in order to start the control of the NMB response
of the patient.
• Step 4 t ≥ t∗: A controller Ki is chosen at each time instant based on the minimization of
the cumulative error between the patient response and the responses of each of the models
in the bank P.
For the purpose of simulation, a model Pj from the bank P is chosen as describing the real
patient dynamics and the corresponding controller Kj removed from the bank K yielding a new
bank of controllers (K\{Kj}). This prevents the switching strategy to ”catch” the controller
associated to the patient model, and makes simulation more realistic, since in real cases the
patient model and hence the corresponding controller are not available. The initial drug bolus is
taken as 500µg/kg for atracurium or 600µg/kg for rocuronium and is given to the patient. The
remaining steps are kept the same as above (from Step 2 to Step 4).
3.3.3 Switching Results
Figs. 3.9, 3.10, 3.11 and Table 3.1 show results of the application of the switching strategy among
a bank of total system mass control laws in order to control the NMB level. For these cases a
bank P with 100 models for atracurium (see Appendix C.1) was used.
Figure 3.9: NMB control simulation with M30 from the bank P of atracurium models.
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Table 3.1: Switching results with atracurium models
Patient Model 30 59 92
Recovery to the Initial Bolus (min) 28 32 37
First Controller K (Random) 17 58 6
Last Controller K 41 97 18
Patient Uss (µg/kg/min) 17,37 5,58 7,34
Real Uss (µg/kg/min) 16,85 5,6 7,36
∆NMB (%) 0,37 0,14 0,06
In the first case (Fig. 3.9), the model P30 was used to simulate the patient dynamics, and so
the controller K30 was removed from the bank K of controllers. As can be seen in Fig. 3.9 and
confirmed in Table 3.1, using modelM30 and applying a typical bolus of 500µg/kg of atracurium,
the recovery time (instant at which the controller is activated) is t∗=28 min and the switching
strategy started with the controller K17. After 300 minutes of simulation the switching strategy
ended with controller K41 with a steady-state dose of 16.85 µg/kg/min. The steady-state dose
necessary to achieve the NMB target of 10% for model P30 is in fact 17.37 µg/kg/min. Since
the difference in the steady-state doses is small, the difference between the final NMB level and
the desired NMB target is only of 0.37% (See Table 3.1).
Figure 3.10: NMB control simulation with M59 from the bank P of atracurium models.
In the second case (Fig. 3.10) the model M59 was used to simulate a patient model and
as a consequence the controller K59 was removed from the controller bank. In this model the
recovery to the initial bolus of 500 µg/kg of atracurium occurred at t∗=32 min and the started
up controller was K58. After 300 minutes of simulation the last controller applied was K97, with
a steady-state dose of 5.6 µg/kg/min. Once the steady-state dose needed for this model in order
to follow the NMB target is 5.58 µg/kg/min the difference between the achieved NMB level and
the desired NMB target is only of 0.14% (See Table 3.1).
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Figure 3.11: NMB control simulation with M92 from the bank P of atracurium models.
Finally, in Fig. 3.11, the model M92 was used to simulate the patient dynamics and the
respective controller K92 was removed from the controller bank. After applying a typical bolus
of 500 µg/kg of atracurium the recovery happened at t∗=37 min and the first applied controller
was K6. After 300 minutes of simulation the switching strategy ended with the controller K18
and a steady-state dose of 7.36 µg/kg/min. Comparing with the steady-state dose needed for
the model to achieve the NMB target, 7.34 µg/kg/min, the difference is very small, and so the
difference between the achieved NMB level and the desired NMB target is only of 0.06% (See
Table 3.1).
In summary, the switching strategy shows good results for the control of the NMB under
administration of atracurium. As can be seen in the left upper plots of Figs. 3.9, 3.10 and 3.11
the NMB level is driven with only small error to the NMB target value (10%) over time. The left
lower plot of each image shows that switching occurs over time, which means that this strategy
responds to the patient dynamics, searching better controllers over time. The right lower plots
show the total system mass of the patient (in blue), the value M∗ that corresponds to the NMB
target according to the patient model (in green), and the different values of M∗ chosen by the
switching strategy over time (in red). As can be seen in these figures the total system mass of the
patient follows the values of M∗ with good accuracy and the controller computes proper values
for M∗, and hence the switching strategy produces good results.
Figs. 3.12, 3.13, 3.14 and Table 3.2 show results concerning the use of the switching strategy
among a bank of total system mass control laws in order to control the NMB level by adminis-
tration of rocuronium. For these cases a bank P with 37 models for rocuronium (see Appendix
C.2) was used.
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Figure 3.12: NMB control simulation with M1 from the bank P of rocuronium models.
Table 3.2: Switching results with rocuronium models
Patient Model 1 19 23
Recovery to the Initial Bolus (min) 28 28 32
First Controller K (Random) 30 29 31
Last Controller K 23 34 13
Patient Uss (µg/kg/min) 5,64 4,4 3,92
Real Uss (µg/kg/min) 5,48 4,4 3,94
∆NMB (%) 0,34 0,007 0,08
In Fig. 3.12, the model used to simulate the patient dynamics is M1, and the respective
controller K1 was removed from the controller bank. As can be seen in Fig. 3.12 and in Table
3.2, after applying a typical bolus of 600 µg/kg of rocuronium, the recovery time is t∗=28 min,
and the switching strategy started up with the controller K30. After 300 minutes of simulation
the last controller applied to this model was K23, corresponding to a steady-state dose of 5.48
µg/kg/min. Since the steady-state dose necessary for modelM1 in order to lead the NMB level
to the NMB target of 10% is 5.64 µg/kg/min, the difference between the achieved NMB level
and the desired NMB target is only of 0.34% (See Table 3.2).
In the second case (Fig. 3.13) the model M19 was used in order to simulate the patient
dynamics, and as a consequence the controller K19 was removed from the controller bank. After
applying a typical bolus of 600 µg/kg of rocuronium the recovery time occurred at t∗=28 min.
The first controller applied by the switching strategy was K29 and at the end of the simulation
the last applied controller was K34 with a steady-state dose of 4.4 µg/kg/min, the same value
as the steady-state dose needed for this model to drive the NMB level to the desired target, and
so the final NMB level was the NMB target of 10% (See Table 3.2).
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Figure 3.13: NMB control simulation with M19 from the bank P of rocuronium models.
Figure 3.14: NMB control simulation with M23 from the bank P of rocuronium models.
Finally in the third case (Fig. 3.14) the modelM23 was used in order to simulate the patient
dynamics and the respective controller K23 was removed from the controller bank. After giving
a bolus of 600 µg/kg of rocuronium the recovery time happened at t∗=32 min, and the switching
strategy started with the controller K31. At the end of the simulation (300 minutes) the controller
used was K13, with a steady-state dose of 3.94 µg/kg/min. Comparing with the steady-state
dose needed by model M23 to achieve the NMB target, 3.92 µg/kg/min, one can see that the
difference is very small. Hence the difference between the achieved NMB level and the desired
NMB target was also very small: only 0.08% (See Table 3.2).
In summary, the switching strategy shows good results for the control of the NMB under
administration of rocuronium. As can be seen in the left upper plots of Figs. 3.12, 3.13 and 3.14
the NMB level is driven with good accuracy to the NMB target value (10%) over time. The left
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lower plot of each image shows that switching occurs over time, as happened for the atracurium
cases. The right lower plots show the total system mass of the patient (in blue), the value M∗ of
the patient model corresponding to the desired NMB target (in green), and the different values
of M∗ chosen by the switching strategy over time (in red). As can be seen in these figures the
total system mass of the patient follows the value M∗ with good accuracy and the controller
computes proper values for M∗, and hence the switching strategy produces good results.
3.3.4 Switching Vs. Parameter Identification via EKF
In order to analyze the switching strategy a comparison was made with the Extended Kalman
Filter (EKF ). The EKF performs the identification of the model parameters used in the total
system mass control law (3.24) in order to control the NMB level.
The Extended Kalman Filter (EKF ) is an adaptation of the filter originally proposed by
Kalman [Kalman (1960)] in order to estimate the states of a linear system. This extension is
aimed at application to nonlinear systems and allows to estimate model parameters by incorpo-
rating them as states (which gives rise to a nonlinear system). The explanation of the Kalman
filter and of the EKF is omitted since it falls out of the scope of this work. Some work re-
lated with the application of the EKF to model parameter identification was made inside the
GALENO project [Almeida (2010), da Silva et al. (2012)].
The EKF algorithm used here was used before in [Almeida (2010), da Silva et al. (2012)] and
properly adapted to this work in order to obtain the necessary data to perform the comparative
study.
For the purpose of obtaining data the bank P with 100 models for atracurium (see Appendix
C.1) and the bank P with 37 models for rocuronium (see Appendix C.2) were used. A simulation
of 300 minutes was performed for each model, where each one was used to simulate the patient
dynamics as previously mentioned. Thereafter the two strategies were analyzed using the follow-
ing as comparison features: total amount of used drug normalized by the patient weight, set-point,
settling time, and tracking quality. Taking into account that discretized models are used, these
parameters are defined as follows:
• The normalized drug amount is given by:
tend∑
k=t∗
u(k), (3.30)
where u(k) (µg/kg/min) is the dose of administered drug at step k, and t∗ is the recovery
time, detected by OLARD.
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• The set-point corresponds to the value (in %) where NMB level stabilizes;
• The settling time is the time that patient’s NMB level takes to reach the set-point value,
with an error not greater than 2%;
• The tracking quality is measured by:
1
n
tend∑
k=settlingtime
√
(r(k)− rref )2, (3.31)
where n=tend - settlingtime, r(k) is the NMB level at step k and rref is the desired
reference value of 10%.
The results of applying the switching strategy and the EKF followed by a total system mass
control law can be visualized in Tables 3.3 (for atracurium), and 3.4 (for rocuronium).
Table 3.3: Comparison between total mass control with Switching and with Extended Kalman
Filter (EKF ) (atracurium)
Total Input (µg/kg) Set-Point (%) Settling Time (min) Ref Track Error (%)
Switching EKF Switching EKF Switching EKF Switching EKF
N Valid 100 100 100 100 100 100 100 100
Mean 6846 8293 9,90 6,33 96 56 0.27 3,90
Median 6118 7629 9,90 6,38 81 58 0.14 3,68
Std. Deviation 2583 2872 0,62 1,64 51 21 0,48 1,70
Range 11292 16342 7,30 8,25 220 86 3,29 8,26
Minimum 3751 4725 6,10 1,40 29 23 0,01 0,49
Maximum 15043 21067 13,40 9,65 249 108 3,31 8,75
Percentiles 25 5014 6177 9,80 5,08 64 37 0,06 2,66
75 8100 9758 10,05 7,59 113 73 0,23 5,12
In Table 3.3 it can be seen that in average, the total mass control with switching spends less
dose than the total mass control with EKF (EKF+TMC ). Also the input values in the switching
are much closer among themselves than the EKF+TMC input values. This can be seen by the
smaller value of the standard deviation, and of the range. The lowest minimum, and the lowest
maximum values also occur for the switching.
As for the set-point reached with these two techniques, switching presents a better mean
NMB value: 9.90% for a desired target of 10%. EKF+TMC presents a mean value of 6.33%,
which is not a good result concerning to the tracking of the NMB reference of 10%. Moreover the
switching has set-point values closer to the average than the EKF+TMC, as can be seen by the
smaller value of the corresponding standard deviation. The set-points achieved in the switching
vary between 6.10% and 13.40%, and the EKF+TMC between 1.40% and 9.65%, showing again
better results with switching.
The bad results verified in the set-point with the EKF+TMC can be explained by the bad
quality in the parameter identification in cases where the recovery to the initial bolus takes to
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long too happen. Such situation is put into evidence in Fig. 3.15. Here it can be seen that with
the increase of the recovery time the achieved set-point is lower.
Figure 3.15: Set-Point achieved with the EKF+TMC as a function of the recovery time from
the initial bolus with atracurium models.
The settling time mean value is higher with the switching than with the EKF+TMC. This con-
clusion is enhanced by the fact that the lowest minimum and the lowest maximum settling times
occur in the EKF+TMC. These results can be explained due to the nature of the EKF+TMC
strategy, which identifies the parameters to be used in the control law when the recovery to
the initial bolus is detected; in opposition, as the name suggests, the switching strategy causes
changes between controllers over time, and only when the last controller is selected the final
set-point is achieved and the settling time is measured.
Finally, analyzing the tracking error (Ref Track Error column) the mean value for switching is
much lower than the one verified for the EKF+TMC. The same happens to all the other variables
in Table 3.3, showing that the switching is better than the EKF+TMC. So it can be concluded
that the switching strategy has a better reference tracking quality than the EKF+TMC strategy.
Table 3.4: Comparison between total mass control with Switching and with Extended Kalman
Filter (EKF ) (rocuronium)
Total Input (µg/kg) Set-Point (%) Settling Time (min) Ref Track Error (%)
Switching EKF Switching EKF Switching EKF Switching EKF
N Valid 37 37 37 37 37 37 37 37
Mean 3577 3627 10,14 9,38 141 94 0,82 1,38
Median 3205 3125 10,10 9,95 137 89 0,67 0,72
Std. Deviation 1903 2093 1,11 2,33 64 32 0,68 1,97
Range 6610 9226 5,35 10,20 248 112 3,29 8,49
Minimum 911 1200 7,85 1,60 48 39 0,02 0,03
Maximum 7521 10425 13,20 11,80 296 151 3,31 8,52
Percentiles 25 2107 2151 9,23 8,98 94 69 0,31 0,20
75 4303 4223 10,63 10,68 170 123 1,20 1,37
Now comparing the switching strategy and the EKF+TMC strategy using rocuronium mod-
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els, it can be seen in Table 3.4 that in average the switching consumes less dose than the
EKF+TMC. Moreover the doses administered during control with switching are more similar
among themselves than with the EKF+TMC, as is evidenced by the lowest value of the standard
deviation and range for the total drug input using switching. The lowest minimum and maximum
drug dose are also obtained with the switching strategy, showing once again that the switching
consumes less dose.
As for the set-point, here the EKF+TMC shows better results for the mean value than in
the case of the atracurium models (9.38% instead of the previous 6.33% for a desired target
of 10%). Comparing the mean value of the switching with the one of the EKF+TMC, both
of them are similar but the value of switching is closer to the NMB target of 10%. Analyzing
the standard deviation and the range the switching strategy has better results for the set-point
than the EKF+TMC : the set-points for the different cases (models) are more similar for the
switching, also the proximity between the minimum and maximum set-point values show that
same conclusion. Once again the higher value obtained for the standard deviation and range
with the EKF+TMC strategy is due to the bad quality in the parameter identification in cases
where the recovery to the initial bolus takes to long too happen, similar to what happened for
the atracurium models (see Fig. 3.16): as a consequence the reference tracking is not good (as
will be seen more ahead).
Figure 3.16: Set-Point achieved with the EKF+TMC as a function of the recovery time from
the initial bolus with rocuronium models.
Studying the settling time, the same that was observed in Table 3.3 prevails here: the settling
time of the switching strategy is higher than for the EKF+TMC. This can be concluded from the
highest value in the corresponding mean value, in the minimum and maximum, as well as in the
range. Once again such result is due to the nature of the switching strategy, as was previously
mentioned.
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Finally, addressing the tracking error (Ref Track Error column), the switching strategy
presents, as for the atracurium models, lower values than the EKF+TMC strategy except for the
percentile 25. Despite that, the differences between the obtained values for the two strategies is
smaller than the one verified with atracurium models. Therefore it can be said that the switching
strategy presents better reference tracking quality than the EKF+TMC but this difference is
not so large as for the atracurium models.
In summary, for the atracurium models, the switching strategy has better results than the
EKF+TMC strategy with respect to the total dose used during NMB control, follows better the
NMB target with a better reference tracking quality, specially when the recovery time to the
initial bolus is prolonged. As for the settling time, the EKF+TMC obtained better results due
to the nature of the switching strategy.
With the rocuronium models, the switching strategy also has better results than the EKF+TMC
strategy with respect to the total dose required for NMB control, follows better the NMB target
because the values obtained for switching are more closer to the target than the ones obtained
with the EKF+TMC. The reference tracking quality is better for the switching with an advan-
tage over the EKF+TMC, which is smaller than the one verified for the atracurium models.
Finally the settling time is better for the EKF+TMC strategy due to the nature of the switching
strategy.
3.3.5 Analyzing the Switching
In order to further study the switching strategy, another comparative study was made using
fixed total mass controllers chosen from different criteria. More concretely the last choice of the
switching controller was compared with the other controllers, in order to find out if the switching
strategy converge to a good controller.
For the purpose of this study both the bank P of 100 atracurium models (see Appendix C.1),
and the bank P of 37 rocuronium models (see Appendix C.2) were used.
The criteria used to choose a controller for the model that simulates the patient dynamics
are the following:
• The last controller resulting from the switching strategy (Switching) (see Appendix A.2);
• The best controller in the controller bank K (containing all the controllers except the one
of the model used to simulate the patient system) to follow the desired reference of 10%
(Ref Track) (see Appendix A.3);
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• The controller tunned for the model with the value of α closest to the one of the patient
model (Alpha) (see Appendix A.4);
• The controller tunned for the model with the value of γ closest to the one of the patient
model (Gamma) (see Appendix A.4);
• The controller tunned for the model with the value of USS (steady-state dose) closest to
the one of the patient model (USS) (see Appendix A.5);
• The controller tunned for the model with the value of Norm 2 closest to the one of the
patient model (Norm2) (see Appendix A.6);
• The controller tunned for the model with the value of the Vinnicombe metric closest to the
one of the patient model (Vinnicombe) (see Appendix A.7);
• The controller tunned for the model with the closest Impulse Response to the one of the
patient model (Impulse) (see Appendix A.8);
• The controller tunned for the model with the closest Step Response to the one of the patient
model (Step) (see Appendix A.8);
Remark : In the last two criteria, the controllers, Impulse and Response, are chosen in function
of the smaller quadratic mean error.
The corresponding chosen controllers are displayed in the tables of Appendix D (for the
atracurium models see Table D.1, and for the rocuronium models see Table D.2).
After the simulation of the NMB control with the total system mass controllers selected by
the previous criteria with the purpose of comparing the controllers choice, the total amount of
used drug normalized by the patient weight, the set-point, the settling time, and the tracking
quality (described in Section 3.3.4) were analyzed.
As a previous note, it should be noticed that the selected controllers with the Alpha proximity,
Norm2 and Vinnicombe metrics, as well as Impulse and Step response proximity are the same,
and so the values obtained with the application of these controllers are the same also, as will
be seen in the following tables. First the results obtained using the atracurium models (see the
models at Appendix C.1) will be presented.
Regarding the total input amount spent during the NMB control, it can be seen in Table 3.5
that in average the last controller of the switching strategy, the controller with the best reference
tracking, the controller with the most similar gamma, and the controller with the most similar
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Table 3.5: Total input amount during total mass control with different total mass controllers
chosen by different metrics (atracurium)
Total Input Control (in µg/kg)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 100 100 100 100 100 100 100 100 100
Mean 6833 6833 7231 6839 6836 7231 7231 7231 7231
Median 6065 6064 6376 6062 6062 6376 6376 6376 6376
Std. Deviation 2555 2591 2998 2581 2582 2998 2998 2998 2998
Range 11309 11481 16149 11481 11481 16149 16149 16149 16149
Minimum 3679 3679 3825 3679 3679 3825 3825 3825 3825
Maximum 14988 15160 19974 15160 15160 19974 19974 19974 19974
Percentiles 25 5013 5013 4959 5013 5013 4959 4959 4959 4959
75 8073 8065 8399 8065 8065 8399 8399 8399 8399
USS exhibit the lowest values. The same happens for the standard deviation showing that,
aside from the lower consumption, these controllers have the most similar values among them.
This conclusion is reinforced by the smaller values in the range. Analyzing the minimum and
maximum values these controllers present the best values. Summarizing the last controller from
the switching along with the controller with the best reference tracking, the gamma controller,
and the Uss controller lead to smaller drug input during the NMB total system mass control.
Table 3.6: Set-Point of the NMB level during total mass control with different total mass con-
trollers chosen by different metrics (atracurium)
Set-Point (in %)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 100 100 100 100 100 100 100 100 100
Mean 9,92 9,93 10,93 9,88 9,90 10,93 10,93 10,93 10,93
Median 9,90 9,93 9,40 9,85 9,90 9,40 9,40 9,40 9,40
Std. Deviation 0,55 0,54 8,69 0,55 0,55 8,69 8,69 8,69 8,69
Range 5,85 5,85 35,9 5,90 5,90 35,9 35,9 35,9 35,9
Minimum 7,55 7,55 0,10 7,55 7,55 0,10 0,10 0,10 0,10
Maximum 13,40 13,40 36,0 13,45 13,45 36,0 36,0 36,0 36,0
Percentiles 25 9,76 9,81 4,01 9,75 9,75 4,01 4,01 4,01 4,01
75 10,05 10,05 16,73 10,05 10,05 16,73 16,73 16,73 16,73
Analyzing the achieved set-point (see Table 3.6), once again the last controller from switching,
the controller with the best reference tracking, the controller with the most similar gamma, and
the controller with the most similar USS show the closest mean values to the desired reference
during the NMB control, of 10%, although the mean values obtained with the other controllers
are not much different. Besides that, the values for the standard deviation show that the other
controllers produce set-point values that have wide variability and so the reference tracking
is not quite satisfactory (this situation will be proven ahead with the results for the tracking
quality). The higher values for the range, as well as the smaller values in the minimum and the
higher values in the maximum that are obtained using the other controllers corroborate that
same conclusion. The standard deviation, range, minimum and maximum values from the first
controllers are quite good. Concluding, once again, the last controller from switching together
with the controller with the best reference tracking, the controller with the most similar gamma,
and the one with the most similar USS present better results in the set-points achieved during
the NMB control with total system mass control law.
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Table 3.7: Settling Time of the NMB level during total mass control with different total mass
controllers chosen by different metrics (atracurium)
Settling Time (in minutes)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 100 100 100 100 100 100 100 100 100
Mean 64 65 70 66 66 70 70 70 70
Median 67 67 68 67 67 68 68 68 68
Std. Deviation 21 22 21 22 22 21 21 21 21
Range 86 87 90 87 87 90 90 90 90
Minimum 25 24 27 24 24 27 27 27 27
Maximum 111 111 117 111 111 117 117 117 117
Percentiles 25 46 47 56 47 47 56 56 56 56
75 81 81 87 82 82 87 87 87 87
Regarding the results for the settling time, in Table 3.7, despite the lower values with the last
controllers of switching, the controllers with the best reference tracking, the controllers with the
most similar gamma, and the controllers with the most similar USS , the difference in relation
with the other controllers is not so significant since the mean values differ from each other from at
most 6 minutes. Also the values from the standard deviation, range, minimum and maximum are
very similar. Therefore the settling time is not enough to distinguish the controller performance.
Table 3.8: Reference tracking error during total mass control with different total mass controllers
chosen by different metrics (atracurium)
Reference Tracking Error (%)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 100 100 100 100 100 100 100 100 100
Mean 0,26 0,24 7,13 0,24 0,24 7,13 7,13 7,13 7,13
Median 0,14 0,12 6,17 0,11 0,11 6,17 6,17 6,17 6,17
Std. Deviation 0,46 0,46 5,19 0,46 0,46 5,19 5,19 5,19 5,19
Range 3,29 3,29 25,94 3,29 3,29 25,94 25,94 25,94 25,94
Minimum 0,02 0,02 0,21 0,02 0,02 0,21 0,21 0,21 0,21
Maximum 3,31 3,31 26,15 3,31 3,31 26,15 26,15 26,15 26,15
Percentiles 25 0,07 0,06 3,37 0,06 0,06 3,37 3,37 3,37 3,37
75 0,26 0,21 9,42 0,21 0,20 9,42 9,42 9,42 9,42
Finally, considering the results for the reference tracking quality (see Table 3.8), it can be
seen that the last controllers from switching, the controllers with the best reference tracking, the
controllers with the most similar gamma, and the controllers with the most similar USS present
the best mean values, once the errors are the lowest. Analyzing the standard deviation and
the range, the lower values presented for these controllers show once again that better reference
tracking can be achieved in comparison with the other controllers (Alpha, Norm2, Vinnicombe,
Impulse and Step). The smaller values for the minimum and maximum error reinforce the same
conclusion, a better reference tracking is achieved with the first controllers, as was previously
seen with respect to the set-point results.
As a conclusion, for atracurium models, the last controller from the switching together with
the controller with the best reference tracking, the controller from the model with the most
similar value of gamma to the one of the patient model, and the controller from the model
with the most similar USS to the one of the patient model present better control because lower
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input doses are required, the reference tracking quality is better, and the set-points achieved are
quite satisfactory in comparison with the desired NMB target of 10%. So one can say that, for
atracurium models, the switching strategy converges to a good controller since this one provides
a good control of the NMB level.
Table 3.9: Total input amount during total mass control with different total mass controllers
chosen by different metrics (rocuronium)
Total Input Control (in µg/kg)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N 37 37 37 37 37 37 37 37 37
Mean 3575 3604 3123 3603 3549 3123 3123 3123 3123
Median 3121 3284 3087 3284 3284 3087 3087 3087 3087
Std. Deviation 1954 1986 1607 1978 1921 1607 1607 1607 1607
Range 6661 6816 6798 6816 6816 6798 6798 6798 6798
Minimum 893 893 924 893 893 924 924 924 924
Maximum 7554 7709 7722 7709 7709 7722 7722 7722 7722
Percentiles 25 2091 2213 1977 2214 2214 1977 1977 1977 1977
75 4370 4442 3637 4331 4331 3637 3637 3637 3637
Analyzing now the results obtained with rocuronium models (see the models at Appendix
C.2), it can be seen that for the total input spent during the NMB control (see Table 3.9)
the controllers of the Alpha proximity, Norm2 and Vinnicombe metrics, and Impulse and Step
proximity lead to less input doses than the other controllers. Despite the minimum and maximum
values being quite similar for all the controllers, the mean values for the first controllers as well
as the standard deviation values, are smaller than the ones for the others. So in a global
appreciation, the last controllers from switching together with the controllers with best reference
tracking, the controllers with the most similar gamma, and the controllers with the most similar
USS show to spend more input dose during the NMB control.
Table 3.10: Set-Point of the NMB level during total mass control with different total mass
controllers chosen by different metrics (rocuronium)
Set-Point (in %)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 37 37 37 37 37 37 37 37 37
Mean 10,14 10,14 13,05 10,08 10,17 13,05 13,05 13,05 13,05
Median 10,15 10,05 11 10,05 10,05 11 11 11 11
Std. Deviation 1,07 0,97 10,30 0,98 0,97 10,30 10,30 10,30 10,30
Range 5,7 5,7 43 5,7 5,7 43 43 43 43
Minimum 7,9 7,9 0,05 7,9 7,9 0,05 0,05 0,05 0,05
Maximum 13,6 13,6 43,05 13,6 13,6 43,05 43,05 43,05 43,05
Percentiles 25 9,55 9,73 4,75 9,63 9,65 4,75 4,75 4,75 4,75
75 10,65 10,65 20,25 10,575 10,65 20,25 20,25 20,25 20,25
With respect to the results for the set-points achieved (see Table 3.10), the last controller
from switching, the controller with the best reference tracking, the gamma proximity controller,
and the USS controller present better results, once the mean set-point values for these controllers
are much closer to the NMB reference of 10%, used during the NMB control, than the mean set-
point values for the other controllers; also the standard deviation of the first controllers is much
smaller than the one verified for the Alpha, Norm2, Vinnicombe, Impulse and Step controllers,
showing that not only the mean behavior of the first controllers is closer to the NMB target, but
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also the range of set-points obtained are closer to the mean values; this situation is reinforced by
the higher values of minimum and the lower values of maximum. Therefore it can be said that
the last controller from switching along with the controller with the best reference tracking, and
the gamma and USS controllers present better set-point results. This better tracking quality will
be confirmed ahead when the results of Table 3.12 are analyzed.
Table 3.11: Settling Time of the NMB level during total mass control with different total mass
controllers chosen by different metrics (rocuronium)
Settling Time (in minutes)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 37 37 37 37 37 37 37 37 37
Mean 86 85 94 88 88 94 94 94 94
Median 76 76 80 85 88 80 80 80 80
Std. Deviation 40 40 43 40 40 43 43 43 43
Range 146 146 172 146 146 172 172 172 172
Minimum 35 35 37 35 35 37 37 37 37
Maximum 180 180 209 180 180 209 209 209 209
Percentiles 25 57 46 58 52 52 58 58 58 58
75 113 117 124 119 119 124 124 124 124
Regarding the settling time (see Table 3.11) once again the controllers from the last switch-
ing, the controller with the best reference tracking, the gamma proximity controller, and the
USS proximity controller have lower mean values, between 85 and 88 minutes, unlike the other
controllers that have a mean value of 94 minutes for settling the NMB level. About the standard
deviation and the minimum values, they are very similar for all the controllers, but when the
range and the maximum values are analyzed the first controllers show again better results, once
they register lower values. Overall the last controller from switching along with the best oﬄine
controller, the controller with the most similar gamma, and the controller with the most similar
USS have better settling times because they reach the set-point earlier than the other controllers.
Table 3.12: Reference tracking error during total mass control with different total mass controllers
chosen by different metrics (rocuronium)
Reference Tracking Error (%)
Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
N Valid 37 37 37 37 37 37 37 37 37
Mean 0,79 0,58 8,21 0,56 0,58 8,21 8,21 8,21 8,21
Median 0,68 0,31 5,74 0,38 0,38 5,74 5,74 5,74 5,74
Std. Deviation 0,66 0,67 6,96 0,65 0,68 6,96 6,96 6,96 6,96
Range 3,19 3,19 32,24 3,19 3,19 32,24 32,24 32,24 32,24
Minimum 0,02 0,02 1,02 0,02 0,02 1,02 1,02 1,02 1,02
Maximum 3,21 3,21 33,26 3,21 3,21 33,26 33,26 33,26 33,26
Percentiles 25 0,28 0,14 3,60 0,18 0,18 3,60 3,60 3,60 3,60
75 1,17 0,71 10,82 0,71 0,71 10,82 10,82 10,82 10,82
Finally considering the tracking quality with respect to the NMB reference level of 10% (see
Table 3.12) it can be seen that the mean error values for the last controller of switching, the
controller with the best reference tracking, the most similar controller by gamma proximity, and
the controller with the most closer USS are smaller. Analyzing the standard deviation, once again
the former controllers show better results with smaller values, as well as for the range, showing
a more similar reference tracking performance and with better quality in all the simulated cases
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with rocuronium models. The lower values for minimum and maximum tracking error reinforce
once again this same conclusion. Therefore the last controller from switching together with the
controller with the best reference tracking, the controller with the most similar gamma, and
the controller with the most similar USS present better reference tracking quality, a main goal
desired in the NMB control.
As a conclusion, for rocuronium models, the last controller from the switching together with
the controller with the best reference tracking, the controller from the model with the most
similar value of gamma to the one of the patient model, and the controller from the model with
the most similar USS to the one of the patient model do not show the best results regarding the
total input required to control the NMB level, but once again (as for the atracurium models) the
reference tracking quality is better, the set-points achieved are closer to the NMB target of 10%,
and now the settling time allows to differentiate the controllers because the former controllers
have lower values. So one can say that, for rocuronium models, the switching strategy converges
to a good controller since this one provides a good control of the NMB level.
3.3.6 Reference Tracking Improvement
Although the switching control scheme can take into account some problems related with the
variations on the patient behavior, like all the previously developed controllers, it is also nonop-
timal, and carries some issues especially related with the reference tracking. Indeed, since the
parameters (α, γ) as well as the value of M∗ for a real patient are unknown, and the bank has a
finite number of controllers, it is expected that the parameters of the control law are not strictly
equal to the real patient parameters, and so a reference steady state tracking error is expected.
In order to overcome this drawback a scheme to improve the tracking quality is here proposed.
This strategy, relying on the NMB response at steady state, performs the online tunning of the
patient parameter γ [Alonso et al. (2008)].
For this purpose the input applied to the patient must be at steady state, uss, and the
corresponding steady state NMB level response, rss, is supposed to be reached.
Notice that, in steady-state, equation (3.8) becomes:
rss =
100
1 +
(
yss
k.C50
)γ∗ , (3.32)
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where γ∗ is the correct value of the parameter γ.
Moreover,
yss = G(0).uss,
where
G(s) =
k1k2k3α
3
(s+ αk1)(s+ αk2)(s+ αk3)
is the reduced parameter model transfer function. Since G(0) = 1→ yss = uss and hence:
rss =
100
1 +
(
uss
k.C50
)γ∗ , (3.33)
Now solving for γ∗ yields:
γ∗ =
ln
(
100
rss
− 1
)
ln
(
uss
k.C50
) . (3.34)
In practice it is assumed that uss and rss are attained when the variation of the values of
u(t) and r(t) are smaller than an adequate threshold.
It turns out that a correct identification of this parameter will lead to the improvement of
the control law, since the value of M∗ = 3.yref only depends of the parameter γ (see (3.11) and
(3.26)). After this step the parameter γ is fixed as γ∗ and each control law u˜i is adapted as:
ui(t) = max(0, u˜i(t))
u˜i(t) = (Σbj)
−1
i [1 · · · 1](−λI −Ai)x(t) + (Σbi)−1λM∗.
(3.35)
Moreover the choice of the controller to be applied at each instant is now made based on
the cumulative quadratic error between the effect concentration response of the patient (ypatient)
and the effect concentration response of the i-th model in the bank (i = 1, . . . , N) (yi).
ei = ypatient − yi
This cumulative error is obtained from the instant where the controller of the patient NMB
level starts using the control law (3.35).
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In order to incorporate this improvement strategy a further step is added to the switching
strategy leading to a fifth step:
• Step 5 (if applied): Corresponds to the reference tracking improvement where γ is fixed as
γ∗ given by (3.34), and the selection of the controller Ki is then based on the minimization
of the cumulative error between the y response of the patient and the yi responses of each
of the models in the bank P in order to obtain αi for bi and Ai of the control law (3.35).
3.3.7 Reference Tracking Improvement Results
Figs. 3.17, 3.18 and 3.19 show the three worst results obtained with the switching strategy
using the bank P of atracurium models (see Appendix C.1). The models that produced these
results where M27, M34, and M38. In Table 3.13 the results obtained in these simulations can
be observed in columns where there is no value for Calibration Time. In all the three cases an
initial bolus of 500 µg/kg was used, and the total time of simulation was 300 minutes.
Table 3.13: Comparison between switching results with atracurium models with and without
reference tracking improvement
Patient Model 27 27 34 34 38 38
Recovery to the Initial Bolus (min) 41 41 47 47 24 24
First Controller K (Random) 74 74 5 5 32 32
Last Controller K 43 80 27 49 30 60
Patient Uss (µg/kg/min) 4,72 4,72 4,5 4,5 23,19 23,19
Real Uss (µg/kg/min) 4,92 4,66 4,72 4,44 17,37 21,03
∆NMB (%) 1,94 0,75 2,6 0,7 3,3 1,03
Calibration Time (min) - 109 - 200 - 74
Figure 3.17: NMB control simulation with M27 from the bank P of atracurium models with no
calibration.
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For the first case, Fig. 3.17, the controller K27, was removed from the controller bank. The
recovery time, and so the instant for the controller started up, was t∗=41 min, and the control
begins with controller K74. By the end of the simulation the controller chosen was K43 with a
steady-state dose of 4.92 µg/kg/min. Comparing with the steady-state dose of 4.72 µg/kg/min,
required to lead the NMB level of this model to the NMB target of 10%, it can be seen that there
is a difference between these doses, leading to a difference between the final NMB level and the
NMB target level (∆NMB) ∆NMB=1.94% (See Table 3.13).
Figure 3.18: NMB control simulation with M34 from the bank P of atracurium models with no
calibration.
In the second case, Fig. 3.18 the controller K34 was removed from the controller bank and
the recovery time occured at t∗=47 min. The control started up with controller K5 and ended
with the controller K27 with a steady-state dose of 4.72 µg/kg/min, different from the required
dose of 4.5 µg/kg/min needed to lead the NMB level to the target value of 10%. Therefore a
difference ∆NMB=2.6% between the final NMB level and the desired NMB target was observed
(See Table 3.13).
For the third case, Fig. 3.19, the controller removed from the controller bank was K38. The
recovery time was t∗=24 min, and at this time the control started up with the controller K32.
By the end of the simulation time the last applied controller was K30 with a steady-state dose
of 17.37 µg/kg/min, very different of the 21.03 µg/kg/min, required to lead the NMB level to
the target of 10%, and so a difference ∆NMB=3.3% between the final NMB level obtained and
the desired NMB target was observed (See Table 3.13).
Figs. 3.20, 3.21, and 3.22 show the results of applying the reference tracking improvement
technique to the cases of Figs. 3.17, 3.18, and 3.19 respectively. The values obtained for these
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Figure 3.19: NMB control simulation with M38 from the bank P of atracurium models with no
calibration.
cases can be visualized in Table 3.13 in the columns where there are values for the Calibration
Time. This time corresponds to the instant where the reference tracking improvement was
applied. As expected the last controller to be used was not the same as previously, the same
happens with the final steady-state dose applied, which obviously leads to different values of
∆NMB.
Figure 3.20: NMB control simulation with M27 from the bank P of atracurium models with
calibration at 109 minutes.
For the first case, Fig. 3.20, a reference tracking improvement to the case of Fig. 3.17 (M27),
the calibration occurred at t=109 min, and the last controller applied after the 300 minutes
of simulation was K80, with a steady-state dose of 4.66 µg/kg/min instead of the dose of 4.92
µg/kg/min (without calibration). As a consequence the difference between the final NMB level
and the NMB target level was decreased from ∆NMB=1.95% to ∆NMB=0.75%, which is a
significant improvement (See Table 3.13).
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Figure 3.21: NMB control simulation with M34 from the bank P of atracurium models with
calibration at 200 minutes.
In the second case, Fig. 3.21, a reference tracking improvement to the case of Fig. 3.18 (M34),
the calibration was applied at minute 200. The final controller was K49 with a steady-state dose
of 4.44 µg/kg/min instead of the dose of 4.72 µg/kg/min (without calibration). Therefore the
difference between the final NMB level and the NMB target level decreased from ∆NMB=2.6%
to ∆NMB=0.7%, once again showing a significant improvement (See Table 3.13).
Figure 3.22: NMB control simulation with M38 from the bank P of atracurium models with
calibration at 74 minutes.
In the third case, Fig. 3.22, a reference tracking improvement to the case of Fig. 3.19 (M38),
the calibration happened at minute 74, and as a consequence the last controller applied was K60
with a steady-state dose of 21.03 µg/kg/min instead of the dose of 17.37 µg/kg/min (without
calibration). Thus the difference between the final NMB level and the NMB target level decreased
from the ∆NMB=3.3% to ∆NMB=1.03%, once again showing a significantly better performance
(See Table 3.13).
53
CHAPTER 3. AUTOMATIC CONTROL
Summarizing, the reference tracking improvement, when properly applied (the input must
remain in a steady-state dose, and the steady-state NMB response to that dose must be achieved),
produces significant improvements to the reference tracking when atracurium models are used,
since the difference between the final NMB level and the NMB target level decrease.
Figs. 3.23, 3.24 and 3.25 show the three worst results obtained with the switching strategy
using the bank P for rocuronium models (see Appendix C.2). The models that produced these
results were M14, M22, and M28. In Table 3.14 the results obtained in these simulations can
be observed in columns where there is no value for the Calibration Time. In all the three cases
an initial bolus of 600 µg/kg was used, and the total time of simulation was 300 minutes.
Table 3.14: Comparison between switching results with rocuronium models with and without
reference tracking improvement
Patient Model 14 14 22 22 28 28
Recovery to the Initial Bolus (min) 93 93 88 88 33 33
First Controller K (Random) 18 18 2 2 15 15
Last Controller K 21 30 14 10 33 14
Patient Uss (µg/kg/min) 1,37 1,37 1,42 1,42 13,09 13,09
Real Uss (µg/kg/min) 1,42 1,36 1,37 1,39 9,03 11,37
∆NMB (%) 1,71 0,82 1,84 1,23 3,24 1,14
Calibration Time (min) - 200 - 180 - 109
Figure 3.23: NMB control simulation withM14 from the bank P of rocuronium models with no
calibration.
In the first case, Fig. 3.23, where the model M14 is used to simulate the patient dynamics,
the respective controller K14 was removed from the controller bank. The recovery time was
t∗=93 min, and the control was initiated with the controller K18, and ended with the controller
K21 with a steady-state dose of 1.42 µg/kg/min leading to a difference between the final NMB
level and the desired NMB target ∆NMB=1.71% (see Table 3.14).
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Figure 3.24: NMB control simulation withM22 from the bank P of rocuronium models with no
calibration.
For the second case, Fig. 3.24, the controller corresponding to the model used to simulate
the patient dynamics, K22, was removed from the controller bank, and when the recovery hap-
pened, t∗=88 min, the control initiate with the controller K2, and ended with the controller
K14 with a steady-state dose of 1.37 µg/kg/min. In comparison with the steady-state dose
of 1.42 µg/kg/min, required to lead the NMB level to the desired NMB target, a difference
∆NMB=1.84% was observed (see Table 3.14).
Figure 3.25: NMB control simulation withM28 from the bank P of rocuronium models with no
calibration.
Then, in the third case, Fig. 3.25 the respective controller to the model used to simulate
the patient dynamics, K28, was removed from the controller bank. The recovery time was t∗=33
min, and the control started with the controller K15, and at the end of the simulation the
controller applied was K33 with a steady-state dose of 9.03 µg/kg/min. This dose is significantly
55
CHAPTER 3. AUTOMATIC CONTROL
different from the dose of 13.09 µg/kg/min, required to drive the NMB level to the desired NMB
target. Therefore a final difference between the achieved NMB level and the desired NMB target
∆NMB=3.24% occurred (see Table 3.14).
Figs. 3.26, 3.27, and 3.28 show the results of the application of the reference tracking im-
provement technique to the cases of Figs. 3.23, 3.24, and 3.25, respectively. The values obtained
with this improvement technique are in the columns where there are values for the Calibration
Time in Table 3.14. As happened in the case of atracurium, the calibration time corresponds to
the instant were the reference tracking improvement was applied. Once more, as expected, the
last controller was not the same as previously, and the same occurred with the final steady-state
dose applied, which obviously leads to different values of ∆NMB.
Figure 3.26: NMB control simulation with M14 from the bank P of rocuronium models with
calibration at 200 minutes.
For the first case, Fig. 3.26, the calibration was applied at minute 200. This time the
final controller was K30, with a steady-state dose of 1.36 µg/kg/min instead of the dose of 1.42
µg/kg/min (without calibration). Therefore the difference between the final NMB level achieved
and the desired NMB target decreased from ∆NMB=1.71% to ∆NMB=0.82%, showing better
tracking results (see Table 3.14).
In the second case, Fig. 3.27, the calibration was applied at minute 180, and the last controller
applied was K10 with a steady-state dose of 1.39 µg/kg/min instead of the previously dose of 1.37
µg/kg/min (without calibration). The difference between the final NMB level achieved and the
NMB target level decreased from ∆NMB=1.84% to ∆NMB=1.23%, revealing an enhancement
of the reference tracking quality once again (see Table 3.14).
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Figure 3.27: NMB control simulation with M22 from the bank P of rocuronium models with
calibration at 180 minutes.
Figure 3.28: NMB control simulation with M28 from the bank P of rocuronium models with
calibration at 109 minutes.
For the third case, in Fig. 3.28, the calibration was applied at minute 109. The final con-
troller applied was K14 with a steady-state dose of 11.37 µg/kg/min instead of the dose of 9.03
µg/kg/min (without calibration). Therefore the difference between the achieved NMB level and
the desired NMB target decreased from ∆NMB=3.24% to ∆NMB=1.14%, showing once more a
significant improvement in the reference tracking quality (See Table 3.14).
In summary, once again, when properly applied (the input must remain in a steady-state
dose, and the steady-state NMB response to that dose must be achieved), the reference tracking
improvement produces significant improvements in the reference tracking quality for rocuronium
models, since the difference between the final NMB level and the desired NMB target is reduced.
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Chapter 4
Clinical Environment
The NMB control strategy presented in this work based on a switching total system mass control
law was implemented at the Unidade Local de Sau´de de Matosinhos - Hospital Pedro Hispano
(ULSM-HPH) with the supervision of the anesthesiologist Dr. Rui Rabic¸o.
In order to apply the NMB control to real patients it was necessary to use the appropiate NMB
control hardware and software, and to follow a suitable protocol defined by the anesthesiologist.
The protocol varies according to the surgery type and the patient characteristics.
4.1 Hardware for NMB Control
Figure 4.1: Datex-Ohmeda modular system for anesthesia monitoring.
The NMB control system applied at the ULSM-HPH consists of:
• A Datex-Ohmeda device (a modular monitoring family with a full line-up of monitors
and accessories, like the anesthesia monitor, a complex solution for anesthesia patient
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Figure 4.2: Alaris GH Pump for drug infusion.
monitoring during surgeries), in Fig. 4.1, along with a NMT (neuromuscular transmission)
module (Fig. 2.3) in order to obtain the NMB level of the patient during surgery;
• A drug delivery system: an Alaris GH syringe pump (Fig. 4.2) is used in order to administer
the muscle relaxant to the patient;
• A computer: a portable computer with two USB serial ports for connecting the Datex-
Ohmeda device and the infusion pump, in order to run the NMB control software.
The Datex-Ohmeda system and the Alaris GH Pump are connected to the portable computer
by RS232-USB cables.
4.2 Software for NMB Control
To perform the NMB control a proper software is necessary in order to read the patient NMB
level from the Datex-Ohmeda system, and then compute the respective NMB control input using
the switching total system mass control strategy. The software must allow the transmission of
that input value to the Alaris GH pump.
For that purpose two programs were used namely the Data Acquisition System and the
Monitoring Control Anesthesia. These programs were developed by researchers of the Galeno
Project.
The first software (Fig. 4.3) does the collection of all the data acquired by the Datex-Ohmeda
system, registers the infusion information related to the syringe pump, and also allows to control
the pump’s infusion rate. It also permits the user to insert special notes about the surgery,
like intubation and incision, and to mark the administration of a manual bolus (when drugs are
administered manually). This software creates three .txt files, one with the values collected from
the Datex-Ohmeda, another with the information about the infusion given by the Alaris GH
pump, and a last one with all the information related to the patient (Gender, Age, Height and
Weight) and to the surgery (protocol, surgery name, special notes and manual bolus).
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Figure 4.3: Data Acquisition System program developed by Galeno researchers.
The second program (Fig. 4.4) has the main objective to perform the NMB control but it
can also realize the plot of some interest variables related with the Datex-Ohmeda and the Alaris
GH pump. This program was developed in the MATLAB environment and was designed in a
modular way so that any user can develop his own NMB control strategy as a MATLAB function
and then incorporate it in the main software.
Figure 4.4: Monitoring and Control in Anesthesia program developed by Galeno researchers.
The program makes a connection with the former one in order to obtain from it the collected
values. In this way the information necessary to perform the NMB control is provided and the
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control input can be determined. Afterwards the Monitoring and Control in Anesthesia program
sends out that input value to the former program so that it imposes it to the Alaris GH Pump.
A more detailed explanation about these two programs can be read in Appendix B.
4.3 Protocol
The protocol used during the surgeries with the application of the switching strategy to control
the NMB level based on a bank of total system mass control laws was designed by the anesthe-
siologist. It varies according to the characteristics of the patient, the type of surgery and the
protocols implemented by the hospital. Since the real cases control was performed at the Unidade
Local de Sau´de de Matosinhos - ULSM, the specific protocol was made by the anesthesiologist
Rui Rabic¸o according to the general protocols implemented at this hospital.
For the hypnotic induction a bolus of propofol was used in order to achieve a quick induction.
After this induction the maintenance was made with sevoflurane, a volatile drug. The choice of
a volatile drug for the maintenance is due to the possibility of using the Datex Ohmeda device
that is able to make the automatic administration of this drug; the anesthesiologist only needs
to define the infusion rate. For analgesia a single bolus of fentanil was used at the beginning.
Finally, for the arreflexia, the drug rocuronium was used. this drug is nowadays the most widely
used due to its special properties, in particular the existence of sugamadex, a drug that makes
the full reversion of the NMB level possible at any time. At the end of the surgery either the
NMB reverser neostigmine with atropine or the sugamadex were used.
The process of general anesthesia with NMB control during surgeries can be summarized as
follows:
• Step 1 Administration of a fentanil bolus.
• Step 2 Administration of a propofol bolus followed by sevoflurane administration when
the BIS signal starts to recover from the propofol bolus.
• Step 3 Calibration of the NMB Sensor.
• Step 4 t = 0: An initial bolus of rocuronium is given to the patient (Automatic adminis-
tration performed by the Monitoring and Control in Anesthesia software).
• Step 5 0 < t < t∗ (before recovery from the initial bolus of rocuronium): The control input
remains zero.
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• Step 6 t = t∗ (t∗ computed by the OLARD algorithm introduced in da Silva et al. (2009)):
A random controller from bankK is chosen in order to start the control of the NMB response
of the patient.
• Step 7 t ≥ t∗: A controller Ki is chosen at each time instant based on the minimization of
the cumulative error between the patient response and the responses of each of the models
in the bank P.
• Step 8 At the end of the surgery: Administration of either the NMB reverser or the
rocuronium antagonist according to the patient characteristics and his/her NMB level at
this stage.
4.4 Results
Figure 4.5: Results of the application of the switching strategy with a bank of total system mass
control laws in a surgery at ULSM-HPH (2012/03/29 Case 2)
In Fig. 4.5 the case collected on March 29th 2012 at ULSM-HPH is represented. At the top
of this figure some information regarding the clinical case can be seen: Protocol (name of the
surgery), ASA, Gender, Age, Weight (kg), and Height (cm) of the patient.
Remark : The ASA information that appears in Figs. 4.5, 4.6, 4.7, 4.8, and 4.9 corresponds to
the ASA classification system that represents the evaluation done by the anesthesiologist about
the general health and well-being of the patient. Usually there are six classes:
1. A normal healthy patient;
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2. A patient with mild systemic disease;
3. A patient with severe systemic disease;
4. A patient with severe systemic disease that is a constant threat to life;
5. A moribund patient who is not expected to survive without the operation;
6. A declared brain-dead patient whose organs are being removed for donor purposes.
Remark : In these real cases the switching signal was not accessible, so the only information
about the occurrence of switching is the change in the rocuronium infusion rate after the recovery
to the initial bolus happened (a sudden change in the drug infusion rate means a switching in
the controller).
The upper plot of Fig. 4.5 contains all the information about the drugs administered to the
patient that have effect on the NMB level. So, initially, around minute 10, the rocuronium bolus
of 50 mg is represented, then, around minute 60, the recovery occurred and the controller started
up with the infusion of rocuronium. At the end, the reverser, neostigmine together with atropine,
was delivered to the patient (around the minute 170).
In the lower plot of Fig. 4.5 the NMB level of the patient during the surgery is plotted in blue
and the NMB target in red. For this case, three artefacts occurred during the surgery, and they
are marked by a green circle. These sudden changes have no reasonable explanation, since if they
were sensor faults these artefacts should have been momentary, and after a while they should
have come back to the previous values, but in this case after the sudden changes the NMB level
stays in those news values. Despite this, the switching control shows to have a good behavior,
once the NMB level was stabilized around the NMB target, although after the second artefact
the stabilization took more time to happen. Therefore in this case the switching control shows
reasonable results, once no abnormal values were registered. The anesthesiologist considered it
a good performance as the NMB level remained within an acceptable interval of NMB values,
in any moment reach high values. The surgeons did not complain about the muscle relaxation
level, and the controller did not deliver an excess of muscle relaxant to the patient.
In Fig. 4.6 the first case collected on April 12th 2012 at ULSM-HPH is represented. At the
top of this figure once again the same information regarding the patient as in Fig. 4.5 can be
seen.
The upper plot contains all the information about the drugs related with the NMB response
that were administered to the patient. In this plot it can be seen that an initial bolus of 50
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Figure 4.6: Results of the application of the switching strategy with a bank of total system mass
control laws in a surgery at ULSM-HPH (2012/04/12 Case 1).
mg was given to the patient around minute 10, at about minute 45 the OLARD algorithm
identified the recovery of the NMB level, and as a consequence the controller began with the
rocuronium infusion. At the end of the surgery, around minute 235, the antagonist sugamadex
was administered to the patient.
The lower plot shows the NMB level of the patient during the surgery (in blue), and the
NMB target (in red). In a quick preview of the NMB signal, it can be seen that the NMB level
remains closely to the NMB target. In a detailed analysis, since the beginning of the control
procedure and until minute 60 the NMB response was stabilized around the target. After that
the NMB level remained slightly under the target, which means that a larger dose than the
required was administered to the patient, but over time the controller was able to follow again
the target (around minute 120). Once again, around minute 140, an artefact appears in the
signal, in the same way as in the case of Fig. 4.5, but once again the controller was able to
adjust the NMB level to the target thereafter. From this point on, and until the end of the
surgery, the NMB level was constantly kept within a small range of values around the target.
The anesthesiologist considered this controller performance good because the NMB level was
kept within a very reasonable interval, and once again no complains from the surgeons were
registered about the muscle paralysis of the patient. The NMB level did not reach any abnormal
value, and the control did not give an overall excessive dose of rocuronium to the patient. So the
goal of liberating the anesthesiologist for more important tasks was achieved. As a final note,
the changes in the rocuronium infusion rate during the control are a sign that switching among
the controllers in the bank occurred.
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Figure 4.7: Results of the application of the switching strategy with a bank of total system mass
control laws in a surgery at ULSM-HPH (2012/04/12 Case 2).
In Fig. 4.7 the second case collected on April 12th 2012 at ULSM-HPH is represented. At the
top of this figure once again the same patient information as in the previous figures is displayed.
The upper plot represents all the information about the NMB drugs administered to the
patient. For this case a rocuronium bolus of 50 mg was administered around minute 10, and the
recovery to this bolus occurred around the minute 50, and therefore the controller was initiated by
that time. In this case there is no record of any reverser or antagonist having been administered
to the patient at the end of the surgery.
The lower plot shows the NMB level of the patient during the surgery (in blue), as well
as the NMB target desired (in red). For this case the NMB control remains in an acceptable
interval from 0 to 20 % approximately. Around minute 60 the controller did some switching,
specially due to the overshoot in the NMB level registered in the beginning of the control; in
order to compensate this, more dose than the required was administered, but afterwards, until
the change of the NMB target from 10% to 5% around minute 140, the NMB level of the patient
followed the NMB target quite well. When the target was reduced, the NMB level decreased
more than expected and remained close to 0% from minute 150 until minute 170. At the end of
the procedure, the same happened again. In general the switching controller was not optimal, but
for the anesthesiologist Dr. Rui Rabic¸o it was satisfactory, since he never had to be concerned
about the patient NMB level during the surgery, no excessively high values were verified, and
once again the surgeons did not complain about undesired patient movements. However this
time the controller gave a little more dose than the required one. Once again, by the changes
66
CHAPTER 4. CLINICAL ENVIRONMENT
occurred in the rocuronium infusion rate, the occurrence of switching can be inferred.
Figure 4.8: Results of the application of the switching strategy with a bank of total system mass
control laws in a surgery at ULSM-HPH (2012/05/10 Case 2).
Fig. 4.8 contains the results acquired on May 10th 2012 at ULSM-HPH. Once again, at the
top of this figure some information about the patient and the surgery is shown.
The upper plot, which presents all the information regarding to the NMB drugs administered
to the patient, shows that an initial bolus of 40 mg was given to the patient around minute 10,
and the recovery occurred about minute 50. At this same moment the controller begins to work
by applying the continuous infusion of rocuronium to the patient. In this case, at the end of the
surgery, the antagonist, sugamadex, was administered to the patient (around minute 260).
The lower plot shows the NMB response of the patient during the surgery (in blue), as well
as the NMB target applied to this case (in red). This case shows a good performance of the
controller. In this surgery the NMB level was always kept between 6 and 14%, and no abnormal
value was registered during the surgery. The infusion rate of rocuronium was neither excessive
not scarce. The surgeons did not complain at any time about the muscle paralysis of the patient,
the anesthesiologist did not have to worry about the muscle relaxation of the patient, and so this
case can be considered very satisfactory. Once again, through the several changes in the infusion
rate of rocuronium it can be inferred that the switching occurred.
Fig. 4.9 shows the case collected on May 31th 2012 at ULSM-HPH. At the top of this figure
once again the same patient information as in the previous figures is displayed.
The upper graphic of Fig. 4.9 displays all the drugs related to the NMB level that were
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Figure 4.9: Results of the application of the switching strategy with a bank of total system mass
control laws in a surgery at ULSM-HPH (2012/05/31 Case 1).
administered to the patient. For this case an initial bolus of 50 mg of rocuronium was given to
the patient around minute 20, around minute 75 the recovery to the initial bolus was detected
and so the NMB control started up with the infusion of rocuronium. At the end of the surgery,
around minute 180, the reverser, neostigmine together with atropine, was administered for a full
reversion of the NMB.
In the lower plot, the patient NMB response is represented (blue line) as well as the NMB
target (red line). During the surgery two artefacts were registered due to the action of the
anesthesiology, who needed to make new accesses for the intravenous drug administration (green
circles): the first one occurred quite after the initial bolus administration, and the second one
right after the recovery to the initial bolus. Although the second one appeared during the NMB
control procedure, the controller was able to adjust to the new situation and to control the NMB
level around the desired target. In general, the NMB level was kept around 6 and 14% (except
when the second artefact happened), and the patient relaxation was never a problem for the
anesthesiologist and for the surgeons. Also the anesthesiologist never needed to take any extra
action to adjust the patient muscle relaxation. Overall it can be considered that the controller
had a good performance. Once again the rocuronium infusion rate changes during the NMB
control indicate that switching has occurred.
As a conclusion it can be said that the switching strategy shows to provide good results for the
NMB level control during general anesthesia. The anesthesiologist needed not interfere to adjust
the level of muscle relaxation of the patient, the surgeons did not complain about the patient
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muscle relaxation, the NMB level was kept between good minimum and maximum values, and
the controller was able to respond to artefacts and sudden changes in the patients NMB level.
Despite these results, some precautions have to be taken into account to ensure a good NMB
level control with the switching strategy. The first one is related with the calibration of the
sensor used to measure the NMB level of the patient. This step of calibration is essential to
know the normal behavior of the patient without the presence of neuromuscular blockade agents
(NMBA) and so to be able to quantify the NMB level during the administration of NMBA. If the
calibration is wrong the values measured during the NMB control will also be wrong. Another
aspect to take into account is the distance between the NMBA access and the intravenous access.
This distance must be as short as possible in order to assure that the NMBA dose computed
by the controller and administered by the infusion pump is delivery to the patient, and not
in the access that connects the NMBA access to the patient intravenous system. Prolonged
sensor faults and external interference in the patient NMB response must be avoided in order
not to compromise the NMB switching criterion and the respective NMB control. Also, it was
necessary to put valves at the end of the NMBA access in order to prevent the reflux of other
drugs administered intravenously, which would modify the NMBA concentration. Finally, if the
patient’s arm could be placed open rather than along the body the NMB signal would be free of
noise and the computation of the error between the patient’s response and the responses of the
models, necessary to implement the switching criterion, would be more accurate. This problem
with the patient’s arm positioning occurred with the signals acquired in the Hospital Geral de
Santo Anto´nio where the surgeries are made with the patient’s arm along the body and the NMB
signal has noise presence. The noise was constant even when the NMB sensor was changed, but
not when the surgery took place with the patient’s arm open.
After starting to take into account the precautions, an improvement of the NMB control
performance was achieved during surgeries.
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Chapter 5
Conclusions
The aim of this work was to study the performance of a switching strategy based on a bank of
total system mass control laws to perform the NMB level control of patients during surgery.
Chapter 2 presented information related with medical aspects, like the definition of general
anesthesia, neuromuscular blockade (NMB) anatomy and physiology, and neuromuscular block-
ade agents (NMBA) like atracurium and rocuronium.
In Chapter 3 all the theoretical work used in this thesis were presented. The compartmental
models, for the PK/PD model and for the new reduced parameter model, describing the linear
part that relates the drug input with the effect concentration, together with the non-linear part,
also for both models, which allow to establish a relationship between the effect concentration
and the obtained NMB level, were described. It is important to notice that the modelling for
atracurium and rocuronium only differs in the patient-dependent parameters and in the value of
the fixed parameter C50. Then the NMB open-loop control law (TCI ) was presented together
with the closed-loop control law with real interest for this work, the total system mass control
law. After the NMB control was explained, the switching strategy was described along with the
criterion used to perform the switching within a bank of pre-designed controllers.
Hereafter the simulated results of the application of this strategy to control the NMB level are
presented. Good control performances with a good reference tracking quality were achieved. The
total system mass of the patient was able to follow the value M∗ performed by the controller and
this switching strategy allowed to compute a better M∗ value over time (closer to the real M∗
value required to drive the patient NMB level to the NMB target level) and so the patient NMB
level was driven to the NMB target level as desired. Therefore it can be said that theoretically
the main goal of having a good closed-loop control was achieved.
After that, a study to evaluate the switching strategy was made through a comparison with
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a well known technique of parameter identification, the Extended Kalman Filter (EKF). So for
the banks of available models (atracurium and rocuronium) a simulation of NMB control with
total system mass control was performed using these two techniques. As a result the switching
strategy shows to perform a better NMB control, specially when the recovery to the initial bolus
is prolonged, this situation is very usual in quick NMB inductions where the initial bolus is higher
than the normal. In these cases the EKF showed to perform a bad identification, which made
the NMB control law lead the NMB level far from the desired target. The switching strategy
presents the advantage not to be dependent from the recovery time to the initial bolus. Also
the switching strategy shows to spend less total input dose, during the NMB control, than the
control law corresponding to the model parameters identified with the EKF. Despite that the
settling time with the switching strategy is much longer, but such situation is due to the way
the strategy is conceived (switching the controller over time). The differences between these two
techniques are more evident with the atracurium models; with the rocuronium models they are
lower but still exist.
Afterwards a study in order to analyze if the switching strategy provides a good controller
over time was made. Several total system mass controllers selected oﬄine with different metrics,
among which the last controller used during the switching strategy, were applied. The last
controller of the switching strategy along with the best controller from the controller bank chosen
oﬄine, the controller with the most similar gamma to the one of the patient model, and the
controller with the most similar USS to the one of the patient model show better results regarding
the total input amount required for the NMB control with atracurium models because they spend
less dose, but not with rocuronium models where they spend more dose. Despite that, these
controllers show better reference tracking quality for both NMBA models and so, even if with
rocuronium models these controllers spend more dose, the reference tracking quality justifies
their qualification as better controllers. As for the settling time, the results obtained are similar
for all the controllers studied. Summarizing, the last controller of the switching procedure shows
to provide a good total system mass control leading to consequent good NMB control results
both for atracurium and rocuronium, proving that the switching provides in the course of time
a good controller for the NMB level control.
Finally in Chapter 3 a technique to perform the reference tracking improvement was pre-
sented. For this purpose a steady-state dose, USS , along with the corresponding achieved steady-
state NMB level are used in order to identify a better approximation for the parameter γ of the
total system control law and thus perform a recalibration of the controller. Therefore the three
worst results obtained with the switching strategy with atracurium models and the three worst
cases with rocuronium models were considered and the respective recalibration was applied to
those cases. It was possible to see that this recalibration strategy provided a better reference
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tracking quality. Although the off-set between the NMB level achieved and the NMB target
desired was not completely eliminated, it has been substantially reduced. For practical purposes
this technique is not optimal because it is hard to obtain steady-state doses and NMB levels and
so a good calibration of the parameter γ is hard to achieve.
In Chapter 4 the practical work related with this thesis was presented. Here all the informa-
tion related with hardware, software and protocol used during the real NMB control cases was
initially explained, and then the results obtained were illustrated graphically. Five real cases
were presented with good NMB control using the switching strategy. After analyzing those cases
it can be concluded that this strategy presents good results when applied in real surgeries. The
NMB level was kept inside an acceptable range (between 5 and 15% more or less), the patient
muscle stiffness was never a point of discussion for the surgeons, the anesthesiologist never have
to perform any manual control on the patient muscle relaxation, and even when sudden changes
in the NMB level occurred the controller was able to respond and again drive the NMB level
closer to the desired target. Also when some momentary sensor faults were verified the controller
continues to work correctly. Another aspect of this control strategy is its ability to adapt to
changes in the patient dynamics in the course of time. Despite these encouraging results some
care is needed in order to avoid a bad controller performance. For example, a good sensor cal-
ibration is essential, it is desirable to place the patient arm opened instead of along the body
(to avoid noise), to use a short access as possible to connect the NMBA access to the patient
intravenous access, and to use reflux valves in order to avoid changes in the NMBA concentration.
In summary, this work shows the performance of a NMB control strategy based on switching
among controllers with a total system mass control law. More important than the exploitation
of this technique are the good results obtained both in theory and in practice. The total system
mass control shows to work properly with switching and this strategy is able to select a good
controller for the patient. Moreover this strategy provides good results even in the presence of
momentary sensor faults and sudden changes, and is also able to respond to the variations in
the patient dynamics over time, which was one of the major problems with the previously used
controllers. Therefore this control scheme is able to overcome not only the intervariability among
patients but also the intravariability.
For the future, the construction of a population model for the action of rocuronium is sug-
gested, in a similar way to what has been done for atracurium models. Thus will allow to generate
any desired bank P of rocuronium models, and as a consequence any desired controller bank K.
This study will make the switching strategy for the NMB control with rocuronium more robust,
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once the bank of controllers will be more complete, and hence more able to fit the wide inter-
and intra-patient system variability.
Another aspect is related to pursuing the application of the switching strategy to real cases
in the operating room, in order to increase the number of acquired data and so to be able to
perform a statistic study to evaluate the switching performance in real cases.
Finally a further study of the filter used to remove artefacts from the NMB signal needs to
be made. Actually a combined FIR+Median+Non Linear filter is used in order to perform such
action, but still some undesired noise or sensor faults are not corrected. The obstacle to the use
of a higher order filter is the increasing of the delay that the filter will incorporate in the NMB
level, which is an undesired situation as it will affect the performance of the NMB control.
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Appendix A
MATLAB Routines
A.1 Simulation of the response to an initial bolus
1 function Offline_Bolus_Inicial_RED
2 clear all
3 clc
4 %% Load da base de dados com os paraˆmetros Alpha e Gamma
5 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
6 load([cd ’\Base de Dados\Alpha_Gamma_Roc_41.mat’])
7 %% Determinar o numero de modelos na base de dados
8 num_modelos = length(NEW_THETA_100(1,:));
9 indice_modelo = [1:1:num_modelos]’;
10 %% Identificac¸a˜o das varia´veis iniciais
11 y_modelos = [];
12 NMB_modelos = [];
13 for l=1:num_modelos
14 NMB_modelos(1,l) = 100; % Definir o primeiro valor de todos os NMBs
15 end
16 h = 20; % Tempo de Discretizac¸a˜o em segundos
17 h = h/60; % Tempo de Discretizac¸a˜o em minutos
18 tempo_simulacao = 300; % Tempo de simulac¸a˜o em minutos
19 tempo_simulacao = tempo_simulacao/h; % Em instantes de amostragem
20 % bolus_inicial = 500/h; % Bolus inicial m ug/kg para o Atracurium
21 bolus_inicial = 600/h; % Bolus inicial em ug/kg para o Rocuronium
22 % c50 = 0.6487*5; % C50 para o Atracurium
23 c50 = 1; % C50 para o Rocuronium
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24 %% Obtenc¸a˜o dos modelos compartimentais.
25 [Ad_REDM,Bd_REDM,x_modelos,gamma_modelos] = modelo_reduzido_modelos
(NEW_THETA_100,h,num_modelos,indice_modelo);
26 %% Simulac¸a˜o
27 for i=1:tempo_simulacao
28 for j=1:num_modelos
29 x_modelos2(:,1) = x_modelos{i,j};
30 Ad_modelos = Ad_REDM{j};
31 Bd_modelos = Bd_REDM{j};
32 if j==1
33 if i==1
34 u_RED(i) = bolus_inicial;
35 else
36 u_RED(i) = 0;
37 end
38 end
39 x_modelos2(:,2) = Ad_modelos*x_modelos2(:,1)+Bd_modelos*u_RED(i);
40 x_modelos{i+1,j} = x_modelos2(:,2);
41 y_modelos(i+1,j) = [0 0 1]*x_modelos2(:,2);
42 NMB_modelos(i+1,j) = [100/(1+((y_modelos(i+1,j)/c50)ˆ
gamma_modelos(j)))];
43 end
44 end
45 %% Plot dos Resultados
46 % Definir a escala de tempo em minutos
47 t=[0:1:tempo_simulacao]; % Criar escala para o eixo do tempo
48 t=t*h; % Converter o eixo do tempo em minutos
49 % Plot das Concentrac¸o˜es de Efeito
50 subplot(2,1,1),plot(t,y_modelos)
51 title(’Concentrac¸a˜o de Efeito’)
52 xlabel(’minutos’)
53 ylabel(’ug/kg’)
54 % Plot dos Relaxamentos Musculares
55 subplot(2,1,2),plot(t,NMB_modelos)
56 title(’Relaxamento Muscular’)
57 xlabel(’minutos’)
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58 ylabel(’% NMB’)
59 end
60
61 function [Ad_REDM,Bd_REDM,x_modelos,gamma_modelos] = modelo_reduzido_modelos
(NEW_THETA_100,h,num_modelos,indice_modelo)
62 k1=1; k2=4; k3=10;
63 x_modelos = [];
64 x_modelos2 = [];
65 for k=1:num_modelos
66 % Obtenc¸a˜o dos paraˆmetros para os modelos simulados
67 alpha_modelos(k) = NEW_THETA_100(1,indice_modelo(k,1));
68 gamma_modelos(k) = NEW_THETA_100(2,indice_modelo(k,1));
69 % Construc¸a˜o das matrizes do modelo compartimental
70 Ac_modelos = [(-k3*alpha_modelos(k)) 0 0;(k2*alpha_modelos(k)) -
(k2*alpha_modelos(k)) 0;0 (k1*alpha_modelos(k)) -(k1*alpha_modelos(k))];
71 Bc_modelos = [k3*alpha_modelos(k) 0 0]’;
72 % Discretizac¸a˜o do sistemas compartimentais
73 [Ad_modelos,Bd_modelos] = c2d(Ac_modelos,Bc_modelos,h);
74 % Guardar as matrizes de todos os modelos do banco de dados
75 Ad_REDM{k} = Ad_modelos;
76 Bd_REDM{k} = Bd_modelos;
77 % Definir os estados iniciais de cada modelo
78 x_RED_modelos = Bc_modelos;
79 x_modelos{1,k} = x_RED_modelos;
80 end
81 end
A.2 Switching Strategy
1 function Control_Law_Switching_RED_Olard
2 clear all
3 clc
4 %% Load da base de dados com os parametros Alpha e Gamma
5 load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’]) % Para o Atracurium
6 % load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’]) % Para o Rocuronium
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7 %% Determinar tamanho da base de dados
8 length1 = length(NEW_THETA_100(1,:));
9 %% Definir algumas varia´veis
10 h = 20; % Tempo de discretizac¸a˜o em segundos.
11 h = h/60; % Tempo de discretizac¸a˜o em minutos.
12 bolus_inicial = 500/h; % Em ug/kg, e no tempo discreto, para o Atracurium
13 % bolus_inicial = 600/h; % Em ug/kg, e no tempo discreto, para o Rocuronium
14 nmb_ref = 10; % Refereˆncia desejada em %
15 lambda = 0.5; % Parametro intrinseco ao controlador
16 c50 = 0.6487*5; % Valor de C50 para o Atracurium
17 % c50 = 1; % Valor de C50 para o Rocuronium
18 %% Definir tempo de simulac¸a˜o e converter para instantes de 20s
19 tempo_simulacao = 300; % Em minutos
20 tempo_simulacao = tempo_simulacao/h; % Em instantes de 20s
21 %% Limpar algumas varia´veis para evitar erros de ca´lculos
22 NMB_paciente = 100;
23 erro = [];
24 ChangePoint = [];
25 M_Estrela = [];
26 flag1 = 0;
27 %% Definir o modelo que vai ser usado para simular o paciente
28 paciente = 1; % Definir qual o modelo do banco de dados usado como paciente
29 parametros_paciente(:,1) = NEW_THETA_100(:,paciente);
30 %% Definir o banco de dados para identificac¸a˜o e controlo do paciente
31 for s=1:length1
32 if s<paciente
33 parametros_modelos(:,s) = NEW_THETA_100(:,s);
34 else if s==paciente
35 else if s>paciente
36 parametros_modelos(:,s-1) = NEW_THETA_100(:,s);
37 end
38 end
39 end
40 end
41 %% Identificac¸a˜o do numero de modelos presentes na base de dados
42 num_modelos = length(parametros_modelos(1,:));
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43 indice_modelo = [1:1:num_modelos]’;
44 %% Obter as variaveis necessa´rias a` simulac¸a˜o
45 [Ad_paciente,Bd_paciente,x_paciente,gamma_paciente,M_E_Paciente,U_SS_Real] =
modelo_reduzido_paciente(parametros_paciente,h,c50,nmb_ref);
46 [Ad_REDM,Bd_REDM,x_modelos,gamma_modelos,Ce_estrela] = modelo_reduzido_
modelos(parametros_modelos,h,num_modelos,indice_modelo,nmb_ref,c50);
47 %% Simulac¸a˜o
48 for i=1:tempo_simulacao
49 for j=1:num_modelos
50 Ad_modelos = Ad_REDM{j};
51 Bd_modelos = Bd_REDM{j};
52 if isempty(ChangePoint)
53 if i==1
54 u_RED(i) = bolus_inicial;
55 else
56 u_RED(i) = 0;
57 end
58 if j==1
59 x_paciente = Ad_paciente*x_paciente+Bd_paciente*u_RED(i);
60 y_paciente(i+1) = [0 0 1]*x_paciente;
61 NMB_paciente(i+1) = [100/(1+((y_paciente(i+1)/c50)
ˆgamma_paciente))];
62 end
63 x_modelos{1,j} = Ad_modelos*x_modelos{1,j}+Bd_modelos*u_RED(i);
64 y_modelos(i+1,j) = [0 0 1]*x_modelos{1,j};
65 NMB_modelos(i+1,j) = [100/(1+((y_modelos(i+1,j)/c50)
ˆgamma_modelos(j)))];
66 else
67 if j==1
68 Ad_control = Ad_REDM{Controlador};
69 Bd_control = Bd_REDM{Controlador};
70 x_control = x_modelos{1,Controlador};
71 M_Estrela2(i) = M_E_Paciente;
72 M_paciente(i) = sum(x_paciente);
73 if flag1==0
74 M_Estrela(i) = 3*Ce_estrela(Controlador);
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75 else
76 Ce_calibrado = [(((100*(c50ˆGamma_Calibrado))-((c50
ˆGamma_Calibrado)*nmb_ref))/nmb_ref)ˆ(1/Gamma_Calibrado)];
77 M_Estrela(i) = 3*Ce_calibrado;
78 end
79 u_RED(i) = min(80,max(0,(((sum(Bd_control))ˆ(-1))*[1 1 1]*
(lambda*eye(3)-Ad_control)*x_control+(((sum(Bd_control))ˆ(-1))
*(1-lambda)*M_Estrela(i)))));
80 x_paciente = Ad_paciente*x_paciente+Bd_paciente*u_RED(i);
81 y_paciente(i+1) = [0 0 1]*x_paciente;
82 NMB_paciente(i+1) = [100/(1+((y_paciente(i+1)/c50)ˆ
gamma_paciente))];
83 end
84
85 x_modelos{1,j} = Ad_modelos*x_modelos{1,j}+Bd_modelos*u_RED(i);
86 y_modelos(i+1,j) = [0 0 1]*x_modelos{1,j};
87 NMB_modelos(i+1,j) = [100/(1+((y_modelos(i+1,j)/c50)
ˆgamma_modelos(j)))];
88
89 erro(i+1,j) = ((NMB_paciente(i+1)-NMB_modelos(i+1,j)).ˆ2);
90 erro2(i+1,j) = ((y_paciente(i+1)-y_modelos(i+1,j)).ˆ2);
91 end
92 end
93 %% Func¸a˜o que identifica automaticamente o inicio da recuperac¸a˜o
94 [ChangePoint] = OLARD_bloco(NMB_paciente);
95 %% Escolher o primeiro controldador aleatoriamente
96 if i==(ChangePoint-1)
97 Controlador = randi(length(NMB_modelos(1,:)),1)
98 end
99 %% Escolher os restantes controladores
100 if i>=ChangePoint & flag1==0
101 erro_acumulado(i+1,:) = sum(erro);
102 min_1 = min(erro_acumulado(i+1,:));
103 Controlador = find(erro_acumulado(i+1,:)==min_1);
104 tabela_Controladores(i+1) = Controlador;
105 elseif i>=ChangePoint & flag1==1
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106 erro_acumulado(i+1,:) = sum(erro2);
107 min_1 = min(erro_acumulado(i+1,:));
108 Controlador = find(erro_acumulado(i+1,:)==min_1);
109 tabela_Controladores(i+1) = Controlador;
110 end
111 %% Calibrac¸a˜o U Steady State
112 if i==270
113 Gamma_Calibrado = log(100/NMB_paciente(i+1))/log(u_RED(i)/c50);
114 flag1 = 1;
115 end
116 end
117 %% Limar algumas varia´veis para o plot
118 NMB_paciente(end) = [];
119 tabela_Controladores(end) = [];
120 erro(end,:) = [];
121 erro_acumulado(end,:) = [];
122 u_RED(1) = 0;
123 %% Construc¸a˜o de algumas varia´veis de interesse
124 Lei_Controlo = tabela_Controladores(end)
125 Switching = tabela_Controladores;
126 Inicio_Recuperacao = ChangePoint*20/60
127 Delta_NMB_SS = abs(NMB_paciente(end)-nmb_ref)
128 Dose_SS = u_RED(end)
129 end
130
131 function [Ad_paciente,Bd_paciente,x_paciente,gamma_paciente,M_E_Paciente,
U_SS_Real] = modelo_reduzido_paciente(parametros_paciente,h,c50,nmb_ref)
132 % Obtenc¸a˜o dos paraˆmetros para o modelo do paciente
133 k1=1; k2=4; k3=10;
134 alpha_paciente = parametros_paciente(1,1);
135 gamma_paciente = parametros_paciente(2,1);
136 % Construc¸a˜o das matrizes do modelo compartimental
137 Ac_paciente = [(-k3*alpha_paciente) 0 0;(k2*alpha_paciente) -(k2*alpha_paciente)
0;0 (k1*alpha_paciente) -(k1*alpha_paciente)];
138 Bc_paciente = [k3*alpha_paciente 0 0]’;
139 % Discretizac¸a˜o do sistema compartimental
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140 [Ad_paciente,Bd_paciente] = c2d(Ac_paciente,Bc_paciente,h);
141 % Definir estado inicial do paciente
142 x_paciente = [];
143 x_paciente = Bc_paciente; % Estado Inicial discreto e´ igual a` matriz B contı´nua
144 % Obter M* do modelo do paciente
145 M_E_Paciente = 3*((((100*(c50ˆgamma_paciente))-((c50ˆgamma_paciente)*nmb_ref))
/nmb_ref)ˆ(1/gamma_paciente));
146 % Obter U Steady State do Paciente
147 Var1 = (alpha_paciente*k1*k2*k3);
148 Var2 = (Var1/((k2-k1)*(k3-k1)))/(alpha_paciente*k1);
149 Var3 = (Var1/((k1-k2)*(k3-k2)))/(alpha_paciente*k2);
150 Var4 = (Var1/((k1-k3)*(k2-k3)))/(alpha_paciente*k3);
151 Var5 = Var2+Var3+Var4;
152 U_SS_Real = c50*((((100/nmb_ref)-1)ˆ(1/gamma_paciente))/Var5);
153 end
154
155 function [Ad_REDM,Bd_REDM,x_modelos,gamma_modelos,Ce_estrela] =
modelo_reduzido_modelos(parametros_modelos,h,num_modelos,indice_modelo,
nmb_ref,c50)
156 k1=1; k2=4; k3=10;
157 x_modelos = [];
158 for k=1:num_modelos
159 % Obtenc¸a˜o dos paraˆmetros para os restantes modelos
160 alpha_modelos(k) = parametros_modelos(1,indice_modelo(k,1));
161 gamma_modelos(k) = parametros_modelos(2,indice_modelo(k,1));
162 % Construc¸a˜o das matrizes dos modelos compartimentais
163 Ac_modelos = [(-k3*alpha_modelos(k)) 0 0;(k2*alpha_modelos(k)) -
(k2*alpha_modelos(k)) 0;0 (k1*alpha_modelos(k)) -(k1*alpha_modelos(k))];
164 Bc_modelos = [k3*alpha_modelos(k) 0 0]’;
165 % Discretizac¸a˜o dos sistemas compartimentais
166 [Ad_modelos,Bd_modelos] = c2d(Ac_modelos,Bc_modelos,h);
167 % Guardar as matrizes de todos os modelos do banco de dados
168 Ad_REDM{k} = Ad_modelos;
169 Bd_REDM{k} = Bd_modelos;
170 % Definir estado inicial dos modelos
171 x_RED_modelos = Bc_modelos;
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172 x_modelos{1,k} = x_RED_modelos;
173 % Obter Ce* dos modelos
174 Ce_estrela(k) = [(((100*(c50ˆgamma_modelos(k)))-((c50ˆgamma_modelos(k))
*nmb_ref))/nmb_ref)ˆ(1/gamma_modelos(k))];
175 end
176 end
177
178 function [ChangePoint] = OLARD_bloco(NMB_paciente)
179 ChangePoint=[];
180 index = 0; holdindex = 0; Subindex = 0;
181 if length(NMB_paciente)>54
182 baseline = mean(NMB_paciente(49-4:49+5));
183 for jj=54:length(NMB_paciente)
184 if (NMB_paciente(jj) > NMB_paciente(jj-1)) && (NMB_paciente(jj)
> baseline+1)
185 index = index + 1; Subindex = Subindex + 1; holdindex =0;
P(Subindex) = NMB_paciente(jj);
186 if (NMB_paciente(jj) > 7) && (Subindex >= 3)
187 index = 15; P(Subindex)=NMB_paciente(jj);
188 end
189 elseif (NMB_paciente(jj) <= NMB_paciente(jj-1)) && (index >= 1)
190 holdindex = holdindex + 1; Subindex = 0;
191 if (NMB_paciente(jj) > 7 ) && (holdindex > 3)
192 index = 0; holdindex =0;
193 elseif(NMB_paciente(jj) <= 7 ) && (holdindex >= 3)
194 index = 0; holdindex =0; Subindex = 0;
195 end
196 end
197 if index >= 15
198 ChangePoint=jj;
199 return
200 end
201 end
202 end
203 end
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A.3 Controller Choice by the Best Reference Tracking
1 function Control_Law_Offline_RED_Olard
2 clear all
3 clc
4 %% Load da base de dados com parametros Alpha e Gamma
5 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
6 load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’])
7 %% Determinar numero de modelos presentes no banco de dados
8 length1 = length(NEW_THETA_100(1,:));
9 for m=1:length1
10 %% Definir variaves iniciais
11 h = 20; % Tempo de discretizac¸a˜o em segundos
12 h = h/60; % Tempo de discretizac¸a˜o em minutos
13 tempo_simulacao = 300; % Tempo de simulac¸a˜o em minutos
14 tempo_simulacao = tempo_simulacao/h; % Em instantes de amostragem
15 % bolus_inicial = 500/h; % Bolus inicial em ug/kg, para o Atracurium
16 bolus_inicial = 600/h; % Bolus inicial em ug/kg, para o Rocuronium
17 nmb_ref = 10; % Target para o NMB
18 lambda = 0.5; % Parametro do controlador da Lei de Controlo de Massa
19 ChangePoint = [];
20 % c50_red = 0.6487*5; % C50 para o Atracurium
21 c50_red = 1; % C50 para o Rocuronium
22 NMB_paciente = 100;
23 NMB_paciente2 = [];
24 NMB_paciente2 = 100;
25 erro = [];
26 %% Retirar da base de dados um modelo para ser o paciente e construc¸a˜o
de uma matriz com os restantes modelos que sobram como base de dados
27 paciente = m; % Modelo usado como paciente
28 parametros_paciente(:,1) = NEW_THETA_100(:,paciente);
29 for e=1:length1
30 if e<paciente
31 parametros_modelos(:,e) = NEW_THETA_100(:,e);
32 else if e==paciente
33 else if e>paciente
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34 parametros_modelos(:,e-1) = NEW_THETA_100(:,e);
35 end
36 end
37 end
38 end
39 %% Identificac¸a˜o do numero de modelos presentes na base de dados
40 num_modelos = length(parametros_modelos(1,:));
41 indice_modelo = [1:1:num_modelos]’;
42 %% Obter as matrizes e parametros necessa´rios a` simulac¸a˜o
43 [Ad_paciente,Bd_paciente,gamma_paciente,x_paciente] =
modelo_reduzido_paciente(parametros_paciente,h,num_modelos);
44 [Ad_REDM,Bd_REDM,x_modelos,gamma_modelos,Ce_estrela] =
modelo_reduzido_modelos(parametros_modelos,h,num_modelos,indice_modelo,
c50_red,nmb_ref);
45 %% Simulac¸a˜o
46 for i=1:tempo_simulacao
47 for j=1:num_modelos
48 x_paciente2(:,1) = x_paciente{i,j};
49 x_modelos2(:,1) = x_modelos{i,j};
50 Ad_modelos = Ad_REDM{j};
51 Bd_modelos = Bd_REDM{j};
52 if isempty(ChangePoint)
53 if i==1
54 u_RED(i,j) = bolus_inicial;
55 else
56 u_RED(i,j) = 0;
57 end
58 x_paciente2(:,2) = Ad_paciente*x_paciente2(:,1)+Bd_paciente
*u_RED(i,j);
59 x_paciente{i+1,j} = x_paciente2(:,2);
60 y_paciente(i+1,j) = [0 0 1]*x_paciente2(:,2);
61 NMB_paciente(i+1,j) = [100/(1+((y_paciente(i+1,j)/c50_red)
ˆgamma_paciente))];
62 if j==1
63 NMB_paciente2(i+1) = NMB_paciente(i+1,j);
64 end
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65 x_modelos2(:,2) = Ad_modelos*x_modelos2(:,1)+Bd_modelos
*u_RED(i,j);
66 x_modelos{i+1,j} = x_modelos2(:,2);
67 y_modelos(i+1,j) = [0 0 1]*x_modelos2(:,2);
68 NMB_modelos(i+1,j) = [100/(1+((y_modelos(i+1,j)/c50_red)
ˆgamma_modelos(j)))];
69 else
70 modelo = indice_modelo(j);
71 Ad_control = Ad_REDM{modelo};
72 Bd_control = Bd_REDM{modelo};
73 x_control = x_modelos{i,j};
74 M_estrela = 3*Ce_estrela(modelo);
75 M_paciente = x_paciente2(1,1)+x_paciente2(2,1)+x_paciente2(3,1);
76 u_RED(i,j) = min(80,max(0,(((sum(Bd_control))ˆ(-1))*[1 1 1]*
(lambda*eye(3)-Ad_control)*x_control(:,1)+(((sum(Bd_control))ˆ
(-1))*(1-lambda)*M_estrela))));
77 x_paciente2(:,2) = Ad_paciente*x_paciente2(:,1)+Bd_paciente
*u_RED(i,j);
78 x_paciente{i+1,j} = x_paciente2(:,2);
79 y_paciente(i+1,j) = [0 0 1]*x_paciente2(:,2);
80 NMB_paciente(i+1,j) = [100/(1+((y_paciente(i+1,j)/c50_red)
ˆgamma_paciente))];
81 x_modelos2(:,2) = Ad_modelos*x_modelos2(:,1)+Bd_modelos
*u_RED(i,j);
82 x_modelos{i+1,j} = x_modelos2(:,2);
83 y_modelos(i+1,j) = [0 0 1]*x_modelos2(:,2);
84 NMB_modelos(i+1,j) = [100/(1+((y_modelos(i+1,j)/c50_red)
ˆgamma_modelos(j)))];
85 erro(i+1,j) = abs(NMB_paciente(i+1,j)-nmb_ref);
86 end
87 end
88 [ChangePoint] = OLARD_bloco(NMB_paciente2);
89 end
90 %% Determinar qual o melhor controlador
91 Erro_Acumulado = sum(erro);
92 min_1 = min(Erro_Acumulado);
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93 modelo1 = find(Erro_Acumulado==min_1);
94 %% Construir varia´veis
95 Leis_de_Controlo(m) = modelo1; % Guardar qual foi o melhor Controlador
96 Inicio_Recuperacao(m) = ChangePoint*h; % Inicio da recurperac¸a˜o em minutos
97 NMB(:,m) = NMB_paciente(:,modelo1); % NMB do paciente com a melhor lei de
controlo
98 All_NMBs{m} = NMB_paciente; % Guardar o NMB do paciente com a melhor lei
de controlo
99 end
100 %% Construir varia´veis
101 numero_paciente = [1:1:length1];
102 Resultados_Offline_RED(1,:) = numero_paciente;
103 Resultados_Offline_RED(2,:) = Leis_de_Controlo;
104 %% Save das varia´veis
105 % save Dados_Offline_RED_Atr Resultados_Offline_RED NMB Inicio_Recuperacao
All_NMBs
106 save Dados_Offline_RED_Roc Resultados_Offline_RED NMB Inicio_Recuperacao
All_NMBs
107 end
108
109 function [Ad_paciente,Bd_paciente,gamma_paciente,x_paciente] =
modelo_reduzido_paciente(parametros_paciente,h,num_modelos)
110 %% Obtenc¸a˜o dos paraˆmetros para o modelo do paciente
111 k1=1; k2=4; k3=10;
112 alpha_paciente = parametros_paciente(1,1);
113 gamma_paciente = parametros_paciente(2,1);
114 %% Construc¸a˜o das matrizes do modelo compartimental
115 Ac_paciente = [(-k3*alpha_paciente) 0 0;(k2*alpha_paciente) -
(k2*alpha_paciente) 0;0 (k1*alpha_paciente) -(k1*alpha_paciente)];
116 Bc_paciente = [k3*alpha_paciente 0 0]’;
117 %% Discretizac¸a˜o do sistema compartimental
118 [Ad_paciente,Bd_paciente] = c2d(Ac_paciente,Bc_paciente,h);
119 %% Definir estado inicial do paciente
120 x_paciente = [];
121 x_paciente2 = [];
122 x_RED_paciente = Bc_paciente; % Estado Inicial discreto = a` matriz B contı´nua
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123 for gg=1:num_modelos
124 x_paciente{1,gg} = x_RED_paciente;
125 end
126 end
127
128 function [Ad_REDM,Bd_REDM,x_modelos,gamma_modelos,Ce_estrela] =
modelo_reduzido_modelos(parametros_modelos,h,num_modelos,indice_modelo,
c50_red,nmb_ref)
129 k1=1; k2=4; k3=10;
130 x_modelos = [];
131 x_modelos2 = [];
132 for k=1:num_modelos
133 % Obtenc¸a˜o dos paraˆmetros para os restantes modelos
134 alpha_modelos(k) = parametros_modelos(1,indice_modelo(k,1));
135 gamma_modelos(k) = parametros_modelos(2,indice_modelo(k,1));
136 % Construc¸a˜o das matrizes dos modelos compartimentais
137 Ac_modelos = [(-k3*alpha_modelos(k)) 0 0;(k2*alpha_modelos(k)) -
(k2*alpha_modelos(k)) 0;0 (k1*alpha_modelos(k)) -(k1*alpha_modelos(k))];
138 Bc_modelos = [k3*alpha_modelos(k) 0 0]’;
139 % Discretizac¸a˜o dos sistemas compartimentais
140 [Ad_modelos,Bd_modelos] = c2d(Ac_modelos,Bc_modelos,h);
141 % Guardar as matrizes de todos os modelos
142 Ad_REDM{k} = Ad_modelos;
143 Bd_REDM{k} = Bd_modelos;
144 % Definir estados iniciais dos modelos
145 x_RED_modelos = Bc_modelos;
146 x_modelos{1,k} = x_RED_modelos;
147 % Obter Ce* dos modelos
148 Ce_estrela(k) = [(((100*(c50_redˆgamma_modelos(k)))-((c50_red
ˆgamma_modelos(k))*nmb_ref))/nmb_ref)ˆ(1/gamma_modelos(k))];
149 end
150 end
151
152 function [ChangePoint] = OLARD_bloco(NMB_paciente2)
153 ChangePoint=[];
154 index = 0; holdindex = 0; Subindex = 0;
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155 if length(NMB_paciente2)>54
156 baseline = mean(NMB_paciente2(49-4:49+5));
157 for jj=54:length(NMB_paciente2)
158 if (NMB_paciente2(jj) > NMB_paciente2(jj-1)) && (NMB_paciente2(jj) >
baseline+1)
159 index = index + 1; Subindex = Subindex + 1; holdindex = 0;
P(Subindex) = NMB_paciente2(jj);
160 if (NMB_paciente2(jj) > 7) && (Subindex >= 3)
161 index = 15; P(Subindex)=NMB_paciente2(jj);
162 end
163 elseif (NMB_paciente2(jj) <= NMB_paciente2(jj-1)) && (index >= 1)
16 4 holdindex = holdindex + 1; Subindex = 0;
165 if (NMB_paciente2(jj) > 7 ) && (holdindex > 3)
166 index = 0; holdindex =0;
167 elseif(NMB_paciente2(jj) <= 7 ) && (holdindex >= 3)
168 index = 0; holdindex =0; Subindex = 0;
169 end
170 end
171 if index >= 15
172 ChangePoint=jj;
173 return
174 end
175 end
176 end
177 end
A.4 Model choice by Alpha or Gamma proximity
1 function Proximidade_Alpha_Gamma_RED
2 clear all
3 clc
4 %% Load da base de dados com os parametros Alpha e Gamma
5 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
6 load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’])
7 %% Determinar o numero de modelos no banco de dados
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8 length1 = length(NEW_THETA_100(1,:));
9 %% Retirar da base de dados um modelo para ser o paciente e construc¸a˜o
de uma matriz com os restantes modelos que sobram da base de dados
10 for i=1:length1
11 paciente = i; % Modelo usado para simular o paciente
12 parametros_paciente(:,1) = NEW_THETA_100(:,paciente);
13 for e=1:length1
14 if e<paciente
15 parametros_modelos(:,e) = NEW_THETA_100(:,e);
16 else if e==paciente
17 else if e>paciente
18 parametros_modelos(:,e-1) = NEW_THETA_100(:,e);
19 end
20 end
21 end
22 end
23 %% Identificac¸a˜o do numero de modelos presentes na base de dados
24 num_modelos = length(parametros_modelos(1,:));
25 indice_modelo = [1:1:num_modelos]’;
26 %% Recolher os parametros Alpha e Gamma
27 [alpha_paciente,gamma_paciente] = modelo_reduzido_paciente
(parametros_paciente);
28 [alpha_modelos,gamma_modelos] = modelo_reduzido_modelos
(parametros_modelos,num_modelos,indice_modelo);
29 %% Determinar o modelo com o alpha mais pro´ximo ao do paciente
30 delta_alpha = abs(alpha_paciente-alpha_modelos);
31 [MIN, modelo2] = min(delta_alpha);
32 Alpha_Proximo(i) = modelo2;
33 %% Determinar o modelo com o gamma mais pro´ximo ao do paciente
34 delta_gamma = abs(gamma_paciente-gamma_modelos);
35 [MIN, modelo3] = min(delta_gamma);
36 Gamma_Proximo(i) = modelo3;
37 end
38 %% Guardar Dados
39 % save Dados_Proximidade_Alpha_Gamma_RED_Atr Alpha_Proximo Gamma_Proximo
40 save Dados_Proximidade_Alpha_Gamma_RED_Roc Alpha_Proximo Gamma_Proximo
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41 end
42
43 function [alpha_paciente,gamma_paciente] = modelo_reduzido_paciente
(parametros_paciente)
44 %% Obtenc¸a˜o dos paraˆmetros para o modelodo paciente
45 alpha_paciente = parametros_paciente(1,1);
46 gamma_paciente = parametros_paciente(2,1);
47 end
48
49 function [alpha_modelos,gamma_modelos] = modelo_reduzido_modelos
(parametros_modelos,num_modelos,indice_modelo)
50 for k=1:num_modelos
51 %% Obtenc¸a˜o dos paraˆmetros para os restantes modelos
52 alpha_modelos(k) = parametros_modelos(1,indice_modelo(k,1));
53 gamma_modelos(k) = parametros_modelos(2,indice_modelo(k,1));
54 end
55 end
A.5 Model choice by Steady-State Input
1 function U_SteadyState_RED
2 clear all
3 clc
4 %% Load do banco de dados com os parametros Alpha e Gamma
5 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
6 load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’])
7 %% Determinar o numero de modelos na banco de dados
8 length1 = length(NEW_THETA_100(1,:));
9 for i=1:length1
10 Alpha = NEW_THETA_100(1,i);
11 Gamma = NEW_THETA_100(2,i);
12 C50 = 1; % C50 para o Rocuronium
13 % C50 = 0.6487*5; % C50 para o Atracurium
14 k1=1;k2=4;k3=10;
15 Var1 = (Alpha*k1*k2*k3);
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16 Var2 = (Var1/((k2-k1)*(k3-k1)))/(Alpha*k1);
17 Var3 = (Var1/((k1-k2)*(k3-k2)))/(Alpha*k2);
18 Var4 = (Var1/((k1-k3)*(k2-k3)))/(Alpha*k3);
19 Var5 = Var2+Var3+Var4;
20 U_SS(i) = C50*((((100/nmb_ref)-1)ˆ(1/Gamma))/Var5);
21 end
22 for d=1:length1
23 %% Obtenc¸a˜o do Uss do paciente
24 paciente = d;
25 Uss_paciente = U_SS(d);
26 %% Obtenc¸a˜o dos Uss dos restantes modelos
27 for s=1:length1
28 if s<paciente
29 Uss_modelos(s) = U_SS(s);
30 else if s==paciente
31 else if s>paciente
32 Uss_modelos(s-1) = U_SS(s);
33 end
34 end
35 end
36 end
37 for j=1:length1-1
38 Delta_Uss(j) = abs(Uss_paciente-Uss_modelos(j));
39 end
40 %% Determinac¸a˜o do modelo mais pro´ximo
41 [MIN, modelo] = min(Delta_Uss);
42 Modelos_Uss(d) = modelo;
43 %% Guardar dados
44 % save Dados_U_SteadyState_Atr Modelos_Uss U_SS
45 save Dados_U_SteadyState_Roc Modelos_Uss U_SS
46 end
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A.6 Model choice by the Norm 2 metric
1 function Metrica_Norma_OpenLoop_RED
2 clear all
3 clc
4 %% Load da base de dados com os parametros Alpha e Gamma
5 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
6 load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’])
7 %% Determinar o numero de modelos no banco de dados
8 length1 = length(NEW_THETA_100(1,:));
9 %% Definir o tempo de discretizac¸a˜o
10 h = 20; % Tempo de discretizac¸a˜o em segundos.
11 h = h/60; % Tempo de discretizac¸a˜o em minutos.
12 %% Retirar da base de dados um modelo para ser o paciente e construc¸a˜o de
uma matriz com os restantes modelos que sobram da base de dados
13 for i=1:length1
14 paciente = i; % Modelo usado para simular o paciente
15 parametros_paciente(:,1) = NEW_THETA_100(:,paciente);
16 for e=1:length1
17 if e<paciente
18 parametros_modelos(:,e) = NEW_THETA_100(:,e);
19 else if e==paciente
20 else if e>paciente
21 parametros_modelos(:,e-1) = NEW_THETA_100(:,e);
22 end
23 end
24 end
25 end
26 %% Identificac¸a˜o do numero de modelos presentes na base de dados
27 if i==1
28 num_modelos = length(parametros_modelos(1,:));
29 indice_modelo = [1:1:num_modelos]’;
30 end
31 %% Obter os sistemas do modelo do paciente e dos modelos da base de dados
32 [sysc_paciente,sysd_paciente] = modelo_reduzido_paciente
(parametros_paciente,h);
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33 [sysc_modelos,sysd_modelos] = modelo_reduzido_modelos(parametros_modelos,
num_modelos,indice_modelo,h);
34 %% Norma dos modelos do paciente e dos modelos da base de dados
35 Norma_Paciente1 = norm(sysc_paciente,2);
36 Norma_Paciente2 = norm(sysd_paciente,2);
37 for k=1:num_modelos
38 sysc_modelos2 = sysc_modelos{k};
39 sysd_modelos2 = sysd_modelos{k};
40 Norma_Modelos1(k) = norm(sysc_modelos2,2);
41 Norma_Modelos2(k) = norm(sysd_modelos2,2);
42 end
43 %% Encontrar modelo com Norma2 mais semelhante ao paciente
44 [Min1,Modelo1] = min(abs(Norma_Paciente1-Norma_Modelos1));
45 Modelos(1,i) = Modelo1;
46 [Min2,Modelo2] = min(abs(Norma_Paciente2-Norma_Modelos2));
47 Modelos(2,i) = Modelo2;
48 end
49 %% Construc¸a˜o da varia´vel com resultados finais
50 numero_paciente = [1:1:length1];
51 Resultados_Norma_RED(1,:) = numero_paciente;
52 Resultados_Norma_RED(2,:) = Modelos(1,:);
53 Resultados_Norma_RED(3,:) = Modelos(2,:);
54 %% Guardar Dados
55 % save Dados_Norma_OpenLoop_RED_Atr Resultados_Norma_RED
56 save Dados_Norma_OpenLoop_RED_Roc Resultados_Norma_RED
57 end
58
59 function [sysc_paciente,sysd_paciente] = modelo_reduzido_paciente
(parametros_paciente,h)
60 %% Obtenc¸a˜o dos paraˆmetros para o modelo do paciente
61 k1=1; k2=4; k3=10;
62 alpha_paciente = parametros_paciente(1,1);
63 %% Construc¸a˜o das matrizes do modelo compartimental
64 Ac_paciente = [(-k3*alpha_paciente) 0 0;(k2*alpha_paciente) -(k2*alpha_paciente)
0;0 (k1*alpha_paciente) -(k1*alpha_paciente)];
65 Bc_paciente = [k3*alpha_paciente 0 0]’;
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66 Cc_paciente = [0 0 1];
67 Dc_paciente = 0;
68 %% Obtenc¸a˜o do sistema compartimental
69 sysc_paciente = ss(Ac_paciente,Bc_paciente,Cc_paciente,Dc_paciente);
70 sysd_paciente = c2d(sysc_paciente,h,’zoh’);
71 end
72
73 function [sysc_modelos,sysd_modelos] = modelo_reduzido_modelos
(parametros_modelos,num_modelos,indice_modelo,h)
74 %% Identificac¸a˜o das varia´veis fixas
75 k1=1; k2=4; k3=10;
76 for k=1:num_modelos
77 num = [];
78 den = [];
79 %% Obtenc¸a˜o dos paraˆmetros para os restantes modelos
80 alpha_modelos(k) = parametros_modelos(1,indice_modelo(k,1));
81 %% Construc¸a˜o das matrizes dos modelos compartimentais
82 Ac_modelos = [(-k3*alpha_modelos(k)) 0 0;(k2*alpha_modelos(k)) -
(k2*alpha_modelos(k)) 0;0 (k1*alpha_modelos(k)) -(k1*alpha_modelos(k))];
83 Bc_modelos = [k3*alpha_modelos(k) 0 0]’;
84 Cc_modelos = [0 0 1];
85 Dc_modelos = 0;
86 %% Obtenc¸a˜o dos sistemas compartimentais
87 sysc_modelos{k} = ss(Ac_modelos,Bc_modelos,Cc_modelos,Dc_modelos);
88 sysd_modelos{k} = c2d(sysc_modelos{k},h,’zoh’);
89 end
90 end
A.7 Model choice by the Vinnicombe metric
1 function Metrica_Vinnicombe_OpenLoop_RED
2 clear all
3 clc
4 %% Load da base de dados com os parametros Alpha e Gamma
5 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
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6 load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’])
7 %% Determinar numero de modelos presentes no banco de dados
8 length1 = length(NEW_THETA_100(1,:));
9 %% Retirar da base de dados um modelo para ser o paciente e construc¸a˜o
de uma matriz com os restantes modelos que sobram da base de dados
10 for i=1:length1
11 paciente = i; % Modelo usado como paciente
12 parametros_paciente(:,1) = NEW_THETA_100(:,paciente);
13 for e=1:length1
14 if e<paciente
15 parametros_modelos(:,e) = NEW_THETA_100(:,e);
16 else if e==paciente
17 else if e>paciente
18 parametros_modelos(:,e-1) = NEW_THETA_100(:,e);
19 end
20 end
21 end
22 end
23 %% Identificac¸a˜o do numero de modelos presentes na base de dados
24 if i==1
25 num_modelos = length(parametros_modelos(1,:));
26 indice_modelo = [1:1:num_modelos]’;
27 end
28 %% Obter as equac¸o˜es de transfereˆncia
29 [tf_paciente] = modelo_reduzido_paciente(parametros_paciente);
30 [tf_modelos] = modelo_reduzido_modelos(parametros_modelos,num_modelos,indice_modelo);
31 %% Me´trica de Vinnicombe
32 for k=1:num_modelos
33 tf_modelos2 = tf_modelos{k};
34 [gap,nugap] = gapmetric(tf_paciente,tf_modelos2);
35 valores_gap(k) = gap;
36 valores_vinnicombe(k) = nugap;
37 end
38 %% Encontrar modelo mais semelhante ao paciente
39 min1_nugap = min(valores_vinnicombe);
40 modelo_nugap = find(min1_nugap==valores_vinnicombe);
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41 Modelos{1,i} = modelo_nugap;
42 xx = length(modelo_nugap);
43 if xx>1
44 modelo_Vinnicombe(i) = modelo_nugap(1);
45 else
46 modelo_Vinnicombe(i) = modelo_nugap;
47 end
48 end
49 %% Construc¸a˜o da varia´vel com resultados finais
50 numero_paciente = [1:1:length1];
51 Resultados_Vinnicombe_RED(1,:) = numero_paciente;
52 Resultados_Vinnicombe_RED(2,:) = modelo_Vinnicombe;
53 Resultados_Vinnicombe_RED(3,:) = modelo_Gap2;
54 %% Guardar Dados
55 % save Dados_Vinnicombe_OpenLoop_RED_Atr Resultados_Vinnicombe_RED Modelos
56 save Dados_Vinnicombe_OpenLoop_RED_Roc Resultados_Vinnicombe_RED Modelos
57 end
58
59 function [tf_paciente] = modelo_reduzido_paciente(parametros_paciente)
60 num = [];
61 den = [];
62 %% Obtenc¸a˜o dos paraˆmetros do modelo do paciente
63 k1=1; k2=4; k3=10;
64 alpha_paciente = parametros_paciente(1,1);
65 gamma_paciente = parametros_paciente(2,1);
66 %% Construc¸a˜o das matrizes do modelo compartimental
67 Ac_paciente = [(-k3*alpha_paciente) 0 0;(k2*alpha_paciente) -
(k2*alpha_paciente) 0;0 (k1*alpha_paciente) -(k1*alpha_paciente)];
68 Bc_paciente = [k3*alpha_paciente 0 0]’;
69 Cc_paciente = [0 0 1];
70 Dc_paciente = 0;
71 %% Obtenc¸a˜o da equac¸a˜o de transfereˆncia
72 [num,den] = ss2tf(Ac_paciente,Bc_paciente,Cc_paciente,Dc_paciente);
73 tf_paciente = tf(num,den);
74 end
75
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76 function [tf_modelos] = modelo_reduzido_modelos(parametros_modelos,
num_modelos,indice_modelo)
77 %% Identificac¸a˜o das varia´veis fixas
78 k1=1; k2=4; k3=10;
79 for k=1:num_modelos
80 num = [];
81 den = [];
82 %% Obtenc¸a˜o dos paraˆmetros dos restantes modelos
83 alpha_modelos = parametros_modelos(1,indice_modelo(k,1));
84 gamma_modelos = parametros_modelos(2,indice_modelo(k,1));
85 %% Construc¸a˜o das matrizes dos modelos compartimentais
86 Ac_modelos = [(-k3*alpha_modelos) 0 0;(k2*alpha_modelos) -
(k2*alpha_modelos) 0;0 (k1*alpha_modelos) -(k1*alpha_modelos)];
87 Bc_modelos = [k3*alpha_modelos 0 0]’;
88 Cc_modelos = [0 0 1];
89 Dc_modelos = 0;
90 %% Obtenc¸a˜o das equac¸o˜es de transfereˆncia
91 [num,den] = ss2tf(Ac_modelos,Bc_modelos,Cc_modelos,Dc_modelos);
92 tf_modelos2 = tf(num,den);
93 tf_modelos{k} = tf_modelos2;
94 end
95 end
A.8 Model choice by Impulse or Step Response proximity
1 function Comp_Impulse_Step_RED
2 clear all
3 clc
4 %% Identificac¸a˜o das varia´veis iniciais
5 h = 20; % Tempo de discretizac¸a˜o em segundos
6 h = h/60; % Tempo de discretizac¸a˜o em minutos
7 tempo_simulacao = 300; % Tempo de simulac¸a˜o em minutos
8 tempo_simulacao = tempo_simulacao/h; % Em instantes discretizados
9 % dose_impulso = 500; % Dose do impulso para o Atracurium
10 dose_impulso = 600; % Dose do impulso para o Rocuronium
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11 % dose_step = 5; % Dose do degrau para o Atracurium
12 dose_step = 6; % Dose do degrau para o Rocuronium
13 % c50_red = 0.6487*5; % C50 para o Atracurium
14 c50_red = 1; % C50 para o Rocuronium
15 %% Load da base de dados com os parametros Alpha e Gamma
16 % load([cd ’\Base de Dados\Alpha_Gamma_Atr_100.mat’])
17 load([cd ’\Base de Dados\Alpha_Gamma_Roc_37.mat’])
18 %% Determinar o numero de modelos no banco de dados
19 length1=length(NEW_THETA_100(1,:));
20 %% Retirar da base de dados um modelo para ser o paciente e construc¸a˜o
de uma matriz com os restantes modelos que sobram da base de dados
21 for i=1:length1
22 paciente = i; % Modelo usado para simular o paciente
23 parametros_paciente(:,1) = NEW_THETA_100(:,paciente);
24 for s=1:length1
25 if s<paciente
26 parametros_modelos(:,s) = NEW_THETA_100(:,s);
27 else if s==paciente
28 else if s>paciente
29 parametros_modelos(:,s-1) = NEW_THETA_100(:,s);
30 end
31 end
32 end
33 end
34 %% Identificac¸a˜o do numero de modelos presentes na base de dados
35 num_modelos = length(parametros_modelos(1,:));
36 indice_modelo = [1:1:num_modelos]’;
37 %% Obter as respostas ao impulso e ao degrau do modelo do paciente e
dos modelos da base de dados
38 [imp_cont_paciente,imp_disc_paciente,step_cont_paciente,step_disc_paciente,
NMB_imp_cont_paciente,NMB_imp_disc_paciente,NMB_step_cont_paciente,
NMB_step_disc_paciente] = modelo_reduzido_paciente(parametros_paciente,
h,dose_impulso,dose_step,tempo_simulacao,c50_red);
39 [imp_cont_modelos,imp_disc_modelos,step_cont_modelos,step_disc_modelos,
NMB_imp_cont_modelos,NMB_imp_disc_modelos,NMB_step_cont_modelos,
NMB_step_disc_modelos] = modelo_reduzido_modelos(parametros_modelos,h,
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dose_impulso,dose_step,tempo_simulacao,num_modelos,indice_modelo,c50_red);
40 %% Comparar as respostas ao impulso e ao degrau
41 for g=1:tempo_simulacao
42 for f=1:num_modelos
43 imp_cont_modelos2 = imp_cont_modelos{f};
44 erro_imp_cont(g,f) = sqrt((imp_cont_paciente(g)-
imp_cont_modelos2(g))ˆ2);
45 step_cont_modelos2 = step_cont_modelos{f};
46 erro_step_cont(g,f) = sqrt((step_cont_paciente(g)-
step_cont_modelos2(g))ˆ2);
47 imp_disc_modelos2 = imp_disc_modelos{f};
48 erro_imp_disc(g,f) = sqrt((imp_disc_paciente(g)-
imp_disc_modelos2(g))ˆ2);
49 step_disc_modelos2 = step_disc_modelos{f};
50 erro_step_disc(g,f) = sqrt((step_disc_paciente(g)-
step_disc_modelos2(g))ˆ2);
51
52 NMB_imp_cont_modelos2 = NMB_imp_cont_modelos{f};
53 erro_NMB_imp_cont(g,f) = sqrt((NMB_imp_cont_paciente(g)-
NMB_imp_cont_modelos2(g))ˆ2);
54 NMB_step_cont_modelos2 = NMB_step_cont_modelos{f};
55 erro_NMB_step_cont(g,f) = sqrt((NMB_step_cont_paciente(g)-
NMB_step_cont_modelos2(g))ˆ2);
56 NMB_imp_disc_modelos2 = NMB_imp_disc_modelos{f};
57 erro_NMB_imp_disc(g,f) = sqrt((NMB_imp_disc_paciente(g)-
NMB_imp_disc_modelos2(g))ˆ2);
58 NMB_step_disc_modelos2 = NMB_step_disc_modelos{f};
59 erro_NMB_step_disc(g,f) = sqrt((NMB_step_disc_paciente(g)-
NMB_step_disc_modelos2(g))ˆ2);
60 end
61 end
62 %% Fazer o somato´rio dos erros das diferenc¸as
63 erro2_imp_cont = sum(erro_imp_cont);
64 erro2_imp_disc = sum(erro_imp_disc);
65 erro2_step_cont = sum(erro_step_cont);
66 erro2_step_disc = sum(erro_step_disc);
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67
68 erro2_NMB_imp_cont = sum(erro_NMB_imp_cont);
69 erro2_NMB_imp_disc = sum(erro_NMB_imp_disc);
70 erro2_NMB_step_cont = sum(erro_NMB_step_cont);
71 erro2_NMB_step_disc = sum(erro_NMB_step_disc);
72 %% Identificar o somato´rio mais pequeno
73 erro_min_imp_cont = min(erro2_imp_cont);
74 erro_min_imp_disc = min(erro2_imp_disc);
75 erro_min_step_cont = min(erro2_step_cont);
76 erro_min_step_disc = min(erro2_step_disc);
77
78 erro_min_NMB_imp_cont = min(erro2_NMB_imp_cont);
79 erro_min_NMB_imp_disc = min(erro2_NMB_imp_disc);
80 erro_min_NMB_step_cont = min(erro2_NMB_step_cont);
81 erro_min_NMB_step_disc = min(erro2_NMB_step_disc);
82 %% Identificar o modelo com o somato´rio mais pequeno
83 modelo_imp_cont = find(erro_min_imp_cont==erro2_imp_cont);
84 modelo_imp_disc = find(erro_min_imp_disc==erro2_imp_disc);
85 modelo_step_cont = find(erro_min_step_cont==erro2_step_cont);
86 modelo_step_disc = find(erro_min_step_disc==erro2_step_disc);
87
88 modelo_NMB_imp_cont = find(erro_min_NMB_imp_cont==erro2_NMB_imp_cont);
89 modelo_NMB_imp_disc = find(erro_min_NMB_imp_disc==erro2_NMB_imp_disc);
90 modelo_NMB_step_cont = find(erro_min_NMB_step_cont==erro2_NMB_step_cont);
91 modelo_NMB_step_disc = find(erro_min_NMB_step_disc==erro2_NMB_step_disc);
92 %% Guardar modelos em varia´veis
93 Modelo_Impulso_Continuo(i) = modelo_imp_cont;
94 Modelo_Impulso_Discreto(i) = modelo_imp_disc;
95 Modelo_Degrau_Continuo(i) = modelo_step_cont;
96 Modelo_Degrau_Discreto(i) = modelo_step_disc;
97
98 Modelo_NMB_Impulso_Continuo(i) = modelo_NMB_imp_cont;
99 Modelo_NMB_Impulso_Discreto(i) = modelo_NMB_imp_disc;
100 Modelo_NMB_Degrau_Continuo(i) = modelo_NMB_step_cont;
101 Modelo_NMB_Degrau_Discreto(i) = modelo_NMB_step_disc;
102 end
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103 %% Guardar dados
104 numero_paciente = [1:1:length1];
105 Resultados_Imp_Step(1,:) = numero_paciente;
106 Resultados_Imp_Step(2,:) = Modelo_Impulso_Continuo;
107 Resultados_Imp_Step(3,:) = Modelo_Degrau_Continuo;
108 Resultados_Imp_Step(4,:) = Modelo_Impulso_Discreto;
109 Resultados_Imp_Step(5,:) = Modelo_Degrau_Discreto;
110
111 Resultados_NMB_Imp_Step(1,:) = numero_paciente;
112 Resultados_NMB_Imp_Step(2,:) = Modelo_NMB_Impulso_Continuo;
113 Resultados_NMB_Imp_Step(3,:) = Modelo_NMB_Degrau_Continuo;
114 Resultados_NMB_Imp_Step(4,:) = Modelo_NMB_Impulso_Discreto;
115 Resultados_NMB_Imp_Step(5,:) = Modelo_NMB_Degrau_Discreto;
116
117 % save Dados_Imp_Step_RED_Atr Resultados_Imp_Step Resultados_NMB_Imp_Step
118 save Dados_Imp_Step_RED_Roc Resultados_Imp_Step Resultados_NMB_Imp_Step
119 end
120
121 function [imp_cont_paciente,imp_disc_paciente,step_cont_paciente,
step_disc_paciente,NMB_imp_cont_paciente,NMB_imp_disc_paciente,
NMB_step_cont_paciente,NMB_step_disc_paciente] = modelo_reduzido_paciente
(parametros_paciente,h,dose_impulso,dose_step,tempo_simulacao,c50_red)
122 %% Limpar varia´veis
123 imp_cont = [];
124 imp_disc = [];
125 step_cont = [];
126 step_disc = [];
127 NMB_imp_cont_paciente = [];
128 NMB_imp_disc_paciente = [];
129 NMB_step_cont_paciente = [];
130 NMB_step_disc_paciente = [];
131 imp_cont_paciente = [];
132 imp_disc_paciente = [];
133 step_cont_paciente = [];
134 step_disc_paciente = [];
135 %% Obtenc¸a˜o dos paraˆmetros para o modelo do paciente
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136 k1=1; k2=4; k3=10;
137 alpha_paciente = parametros_paciente(1,1);
138 gamma_paciente = parametros_paciente(2,1);
139 %% Construc¸a˜o das matrizes do modelo compartimental
140 Ac_paciente = [(-k3*alpha_paciente) 0 0;(k2*alpha_paciente) -
(k2*alpha_paciente) 0;0 (k1*alpha_paciente) -(k1*alpha_paciente)];
141 Bc_paciente = [k3*alpha_paciente 0 0]’;
142 Cc_paciente = [0 0 1];
143 Dc_paciente = 0;
144 %% Discretizac¸a˜o do sistema compartimental
145 sysc_paciente=ss(Ac_paciente,Bc_paciente,Cc_paciente,Dc_paciente);
146 sysd_paciente=c2d(sysc_paciente,h,’zoh’);
147 %% Obtenc¸a˜o das Respostas ao Impulso e ao Degrau para o Modelo do Paciente
148 % Em tempo contı´nuo
149 [imp_cont,t] = impulse(sysc_paciente,0:1:(tempo_simulacao-1));
150 [step_cont,t] = step(sysc_paciente,0:1:(tempo_simulacao-1));
151 imp_cont_paciente = imp_cont.*dose_impulso;
152 step_cont_paciente = step_cont.*dose_step;
153 for g=1:length(imp_cont)
154 NMB_imp_cont_paciente(g) = [100/(1+(((imp_cont(g)*dose_impulso)/c50_red)
ˆgamma_paciente))];
155 NMB_step_cont_paciente(g) = [100/(1+(((step_cont(g)*dose_step)/c50_red)
ˆgamma_paciente))];
156 end
157 % Em tempo discreto
158 [imp_disc,t] = impulse(sysd_paciente,0:h:(tempo_simulacao-1)/3);
159 [step_disc,t] = step(sysd_paciente,0:h:(tempo_simulacao-1)/3);
160 imp_disc_paciente = imp_disc.*dose_impulso;
161 step_disc_paciente = step_disc.*dose_step;
162 for g=1:length(imp_disc)
163 NMB_imp_disc_paciente(g) = [100/(1+(((imp_disc(g)*dose_impulso)/c50_red)
ˆgamma_paciente))];
164 NMB_step_disc_paciente(g) = [100/(1+(((step_disc(g)*dose_step)/c50_red)
ˆgamma_paciente))];
165 end
166 end
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167
168 function [imp_cont_modelos,imp_disc_modelos,step_cont_modelos,
step_disc_modelos,NMB_imp_cont_modelos,NMB_imp_disc_modelos,
NMB_step_cont_modelos,NMB_step_disc_modelos] = modelo_reduzido_modelos
(parametros_modelos,h,dose_impulso,dose_step,tempo_simulacao,num_modelos,
indice_modelo,c50_red)
169 %% Limpar varia´veis
170 imp_cont = [];
171 imp_disc = [];
172 step_cont = [];
173 step_disc = [];
174 NMB_imp_cont = [];
175 NMB_imp_disc = [];
176 NMB_step_cont = [];
177 NMB_step_disc = [];
178 imp_cont_modelos = [];
179 imp_disc_modelos = [];
180 step_cont_modelos = [];
181 step_disc_modelos = [];
182 %% Identificac¸a˜o das varia´veis fixas
183 k1=1; k2=4; k3=10;
184 for k=1:num_modelos
185 %% Obtenc¸a˜o dos paraˆmetros para os restantes modelos
186 alpha_modelos(k) = parametros_modelos(1,indice_modelo(k,1));
187 gamma_modelos(k) = parametros_modelos(2,indice_modelo(k,1));
188 %% Construc¸a˜o das matrizes dos modelos compartimentais
189 Ac_modelos = [(-k3*alpha_modelos(k)) 0 0;(k2*alpha_modelos(k)) -
(k2*alpha_modelos(k)) 0;0 (k1*alpha_modelos(k)) -(k1*alpha_modelos(k))];
190 Bc_modelos = [k3*alpha_modelos(k) 0 0]’;
191 Cc_modelos = [0 0 1];
192 Dc_modelos = 0;
193 %% Discretizac¸a˜o dos sistemas compartimentais
194 sysc_modelos = ss(Ac_modelos,Bc_modelos,Cc_modelos,Dc_modelos);
195 sysd_modelos = c2d(sysc_modelos,h,’zoh’);
196 %% Obtenc¸a˜o das Respostas ao Impulso e ao Degrau para os restantes modelos
197 % Em tempo contı´nuo
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198 [imp_cont,t] = impulse(sysc_modelos,0:1:(tempo_simulacao-1));
199 [step_cont,t] = step(sysc_modelos,0:1:(tempo_simulacao-1));
200 imp_cont_modelos{k} = imp_cont.*dose_impulso;
201 step_cont_modelos{k} = step_cont.*dose_step;
202 for g=1:length(imp_cont)
203 NMB_imp_cont(g) = [100/(1+(((imp_cont(g)*dose_impulso)/c50_red)
ˆgamma_modelos(k)))];
204 NMB_step_cont(g) = [100/(1+(((step_cont(g)*dose_step)/c50_red)
ˆgamma_modelos(k)))];
205 end
206 NMB_imp_cont_modelos{k} = NMB_imp_cont;
207 NMB_step_cont_modelos{k} = NMB_step_cont;
208 % Em tempo discreto
209 [imp_disc,t] = impulse(sysd_modelos,0:h:(tempo_simulacao-1)/3);
210 [step_disc,t] = step(sysd_modelos,0:h:(tempo_simulacao-1)/3);
211 imp_disc_modelos{k} = imp_disc.*dose_impulso;
212 step_disc_modelos{k} = step_disc.*dose_step;
213 for g=1:length(imp_cont)
214 NMB_imp_disc(g) = [100/(1+(((imp_disc(g)*dose_impulso)/c50_red)
ˆgamma_modelos(k)))];
215 NMB_step_disc(g) = [100/(1+(((step_disc(g)*dose_step)/c50_red)
ˆgamma_modelos(k)))];
216 end
217 NMB_imp_disc_modelos{k} = NMB_imp_disc;
218 NMB_step_disc_modelos{k} = NMB_step_disc;
219 end
220 end
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GALENO Software
B.1 Datex SAD - Data Acquisition
The program Datex SAD allows the user to collect all the data related with the anesthesia
performed during a surgery. This program collects all the data obtained from the Datex Ohmeda
equipment and the drug infusion pumps, and was developed by researchers of the GALENO
project.
Besides the data acquisition, this program allows the user to see the data values collected,
insert notes about the surgery (like instant of intubation, incision, and other things) and any
bolus administered manually, to register the patient information, the name and the protocol of
the surgery, among other aspects related with the surgery.
Figure B.1: Datex SAD Program - Status Separator.
Fig. B.1 presents the Status separator of the Datex SAD program. Here, any information
that the program needs to transmit to the user is represented, such as errors occurred, and tests
performed to the connection between the computer and the Datex Ohmeda equipment and drug
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pump infusions.
Figure B.2: Datex SAD Program - Setup Separator.
Fig. B.2 presents the Setup separator of the Datex SAD program. This part allows the user
to define the drug of each pump infusion, as well as the drug concentration, the sampling time
of the Datex Ohmeda and infusion pump data, the path to save all the data collected, among
other minor things.
Figure B.3: Datex SAD Program - Main Data Separator.
Fig. B.3 shows the Separator that allows the user to see the values acquired from Datex
Ohmeda equipment like BIS signal, BIS-SQI signal, TOF signal, and from the drug infusion
pumps like infusion rate.
Fig. B.4 represents the Special Notes separator, where the user can register all the information
related with the surgery and the patient, like:
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Figure B.4: Datex SAD Program - Special Notes Separator.
• Patient Gender, Age, Height, Weight and ASA;
• Name of the surgery;
• Protocol of the surgery;
• NMB sensor used.
Also, the user is able to insert any bolus administered manually to the patient, by recording
the name, dose and instant of administration of the drug. Other possibility of this separator is the
possibility to insert any desirable note at any instant during the surgery, and so any remarkable
aspect of the surgery can be recorded.
Figure B.5: Datex SAD Program - VAI Bolus Separator.
Fig. B.5 shows the separator that allows the user to give a bolus through a direct order sent
to the drug infusion pump.
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B.2 Monitoring and Control in Anesthesia
The second program, called Monitoring and Control in Anesthesia is developed in a MATLAB
environment by GALENO researchers, and has the main goal to monitoring the process of
anesthesia and also to perform the automatic control of the NMB level, if desired.
Figure B.6: Monitoring and Control in Anesthesia Program.
In Fig. B.6 the interface of this program can be seen. This program receives data collected
by the former program and allows the visualization of that data in function of time. Also, this
program allows the control of the NMB; for this purpose, the user only needs to enable the pump
(in the upper left corner) and choose the NMB control function. For that, the user must have
the NMB control functions, or if desired, create a new one. This program works in a modular
way, and in order to perform a new control the user only needs to make the control function and
incorporate it in this program.
This program is also able to working oﬄine as an important tool to analyze and study the
data collected previously.
Another function of this software is their ability to decode data collected from the Datex
Ohmeda equipment by the Datex SAD software. That data is collect in binary code and a
translation into decimal code is necessary, in order to become that information easily interpreted.
Furthermore the data collected from the drug infusion pumps is placed together with the former
decoded data in a same file (a .mat and a .txt file). The user can choose which data is to
transcribed to this files. Using the Setup button the desired variables can be chosen from a list
116
APPENDIX B. GALENO SOFTWARE
Figure B.7: Data Decoder and NMB Synchronizer.
with all the collected variables (Fig. B.7, DATEX & PUMP Data Decoder).
In this program, the user can also synchronize all the data related with the NMB process
(muscle relaxant bolus and/or infusions and TOF Twitch1 signal) (Fig. B.7, NMB Synchronizer).
This program is able to define the beginning of the TOF Twitch1 signal (when the first muscle
relaxant bolus is administered) and the end (when the reverser or antagonist is given to the
patient). A FIR+Median+Nonlinear filter is applied to the former signal in order to eliminate
momentary artefacts. All the information about bolus and/or infusions of NMB agents is also
synchronized together with the TOF Twitch1 signal. After that the user can perform a plot of
that same data at any time in order to see the synchronized data.
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Appendix C
Bank of Models
C.1 Bank of Atracurium Models
Table C.1: Bank P of 100 atracurium models
Model Alpha Gamma Model Alpha Gamma Model Alpha Gamma
1 0,044825 2,246444 35 0,035803 3,761446 69 0,031645 3,98684
2 0,041211 2,973995 36 0,035529 3,434949 70 0,039477 3,279347
3 0,037808 1,855902 37 0,03927 2,948437 71 0,044602 2,226665
4 0,039477 2,025008 38 0,034499 1,117047 72 0,038253 2,89103
5 0,033515 4,541045 39 0,037355 4,599891 73 0,041705 2,221494
6 0,048703 1,805011 40 0,048026 2,247864 74 0,037062 2,382454
7 0,037713 2,861148 41 0,042657 1,812593 75 0,051218 3,081781
8 0,049477 1,306051 42 0,038965 1,333677 76 0,04317 2,437369
9 0,038941 2,274889 43 0,032347 3,045493 77 0,028146 2,293676
10 0,042818 1,886052 44 0,036958 5,276774 78 0,037572 4,407872
11 0,029811 2,88261 45 0,03824 2,952315 79 0,028174 2,329105
12 0,03349 3,956473 46 0,034253 3,732466 80 0,043878 2,724829
13 0,045396 3,181219 47 0,035452 2,610205 81 0,039743 1,942959
14 0,033817 4,182405 48 0,039871 3,552253 82 0,041292 2,245287
15 0,040894 2,632453 49 0,047662 1,367506 83 0,042835 2,750104
16 0,035324 3,264164 50 0,025507 4,793415 84 0,049133 3,076152
17 0,036584 1,926236 51 0,031476 3,57673 85 0,035545 2,477095
18 0,030266 2,683396 52 0,04453 2,21595 86 0,036573 3,020124
19 0,030641 4,637471 53 0,040921 2,66494 87 0,04114 2,317859
20 0,04358 3,193266 54 0,035816 4,597099 88 0,043534 2,4034
21 0,037106 3,089448 55 0,039865 2,57324 89 0,031392 2,057052
22 0,032983 1,950344 56 0,032074 3,967723 90 0,034291 2,719511
23 0,033157 3,228414 57 0,031856 1,966477 91 0,037601 4,294171
24 0,042751 2,747081 58 0,039268 3,771905 92 0,025354 2,690111
25 0,03704 2,355365 59 0,047352 4,047775 93 0,044781 1,538782
26 0,040488 2,76778 60 0,042008 2,03076 94 0,031832 4,977276
27 0,039756 5,844767 61 0,034518 2,037591 95 0,044745 3,415907
28 0,042052 2,113837 62 0,042909 1,771183 96 0,033047 3,756672
29 0,039779 1,515875 63 0,035947 3,429255 97 0,041262 1,549427
30 0,030303 1,309313 64 0,033359 2,265309 98 0,042476 4,020024
31 0,039622 2,001249 65 0,034858 2,717931 99 0,036354 2,243404
32 0,044547 1,890872 66 0,033955 1,814073 100 0,040799 1,694015
33 0,041872 1,683731 67 0,036166 3,810206
34 0,025775 6,717481 68 0,040797 1,959553
Table C.1 contains the 100 atracurium models used to build the bank P for the atracurium
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drug. From this bank P the total mass system control law was tuned for each model leading to
a bank K with total mass system controllers for atracurium.
C.2 Bank of Rocuronium Models
Table C.2: Bank P of 41 rocuronium models
Model Alpha Gamma Model Alpha Gamma
1 0,054415 1,269884 22 0,054164 1,663375
2 0,038213 1,7086 23 0,068183 1,482369
3 0,058058 1,446245 24 0,078358 1,414203
4 0,010252 3,79457 25 0,031073 1,024188
5 0,025788 4,447869 26 0,031736 6,324634
6 0,065598 1,793064 27 0,052867 1,608939
7 0,036549 2,626389 28 0,081144 1,291639
8 0,034114 2,480481 29 0,027712 1,057524
9 0,093514 1,462093 30 0,033816 1,392472
10 0,030824 2,024059 31 0,044985 1,546866
11 0,070261 1,562036 32 0,028992 0,854272
12 0,020998 6,456394 33 0,02354 1,49399
13 0,031634 3,699414 34 0,027631 3,67053
14 0,05355 2,074754 35 0,030673 1,310781
15 0,081388 0,986952 36 0,039037 1,602996
16 0,060556 1,601377 37 0,051239 1,056976
17 0,030002 6,916275 38 0,038301 0,998537
18 0,045182 2,178904 39 0,062052 1,482878
19 0,037963 2,395231 40 0,030789 3,556661
20 0,095264 5,022601 41 0,03945 1,146665
21 0,091863 1,748396
Table C.3: Bank P of 37 rocuronium models
Model Alpha Gamma Model Alpha Gamma
1 0,054415 1,269884 20 0,078358 1,414203
2 0,038213 1,7086 21 0,031073 1,024188
3 0,058058 1,446245 22 0,031736 6,324634
4 0,065598 1,793064 23 0,052867 1,608939
5 0,036549 2,626389 24 0,081144 1,291639
6 0,034114 2,480481 25 0,027712 1,057524
7 0,093514 1,462093 26 0,033816 1,392472
8 0,030824 2,024059 27 0,044985 1,546866
9 0,070261 1,562036 28 0,028992 0,854272
10 0,031634 3,699414 29 0,02354 1,49399
11 0,05355 2,074754 30 0,027631 3,67053
12 0,081388 0,986952 31 0,030673 1,310781
13 0,060556 1,601377 32 0,039037 1,602996
14 0,030002 6,916275 33 0,051239 1,056976
15 0,045182 2,178904 34 0,038301 0,998537
16 0,037963 2,395231 35 0,062052 1,482878
17 0,091863 1,748396 36 0,030789 3,556661
18 0,054164 1,663375 37 0,03945 1,146665
19 0,068183 1,482369
Table C.2 contains the 41 models obtained from a set of real data acquired during 41 surgeries.
For each of these real cases, the parameters α and γ were identified, and the corresponding models
were taken as the bank for rocuronium drug. The models 4, 5, 12, and 20 (red models in table
C.2) were discarded because no good NMB control can be to obtain with the switching strategy.
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This led to table C.3. These models were used to build the bank P for the rocuronium drug.
From this bank P the total system mass control law was tuned for each model leading to a bank
K with total system mass controllers for rocuronium.
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Appendix D
Controller Choice (in Section
3.3.5)
Table D.1: Controllers chosen by different metrics for atracurium models
Patient Model Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
1 39 39 92 81 81 92 92 92 92
2 44 44 96 44 44 96 96 96 96
3 40 9 6 9 9 6 6 6 6
4 59 59 69 59 59 69 69 69 69
5 53 53 11 53 53 11 11 11 11
6 40 40 83 40 40 83 83 83 83
7 10 71 3 10 10 3 3 3 3
8 41 29 83 29 29 83 83 83 83
9 39 63 41 63 63 41 41 41 41
10 31 31 82 31 31 82 82 82 82
11 7 71 17 71 71 17 17 17 17
12 55 55 5 55 55 5 5 5 5
13 19 19 1 19 19 1 1 1 1
14 90 90 65 90 90 65 65 65 65
15 46 52 52 46 46 52 52 52 52
16 69 69 46 69 69 46 46 46 46
17 21 80 85 80 80 85 85 85 85
18 52 52 29 91 91 29 29 29 29
19 53 38 29 38 38 29 29 29 29
20 13 13 87 13 13 87 87 87 87
21 42 74 73 74 74 73 73 73 73
22 56 80 95 80 80 95 95 95 95
23 16 16 95 20 16 95 95 95 95
24 82 82 10 82 82 10 10 10 10
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25 73 73 73 78 73 73 73 73 73
26 82 82 67 82 82 67 67 67 67
27 43 43 80 43 43 80 80 80 80
28 59 88 59 88 88 59 59 59 59
29 92 92 27 92 92 27 27 27 27
30 41 8 18 8 8 18 18 18 18
31 4 4 80 4 4 80 80 80 80
32 10 10 51 10 10 51 51 51 51
33 99 99 59 99 99 59 59 59 59
34 27 27 49 27 27 49 49 49 49
35 95 57 53 95 95 53 53 53 53
36 62 62 84 62 62 84 84 84 84
37 44 44 57 44 44 57 57 57 57
38 30 30 60 8 8 60 60 60 60
39 53 53 77 53 53 77 77 77 77
40 1 1 48 1 1 48 48 48 48
41 6 65 24 65 65 24 24 24 24
42 8 30 9 30 30 9 9 9 9
43 85 83 55 85 85 55 55 55 55
44 93 93 25 93 93 25 25 25 25
45 37 37 71 37 37 71 71 71 71
46 35 95 89 95 95 89 89 89 89
47 15 15 36 15 15 36 36 36 36
48 50 50 54 50 50 54 54 54 54
49 42 42 58 42 42 58 58 58 58
50 93 19 91 19 19 91 91 91 91
51 48 48 88 48 48 88 88 88 88
52 72 72 32 72 72 32 32 32 32
53 18 18 15 18 18 15 15 15 15
54 39 39 35 39 39 35 35 35 35
55 47 47 48 47 47 48 48 48 48
56 12 68 56 12 12 56 56 56 56
57 22 22 93 67 67 93 93 93 93
58 35 35 37 35 35 37 37 37 37
59 97 97 49 97 97 49 49 49 49
60 4 4 28 4 4 28 28 28 28
61 4 60 38 60 60 38 38 38 38
62 6 65 82 6 6 82 82 82 82
63 36 36 54 36 36 54 54 54 54
64 98 9 12 9 9 12 12 12 12
65 89 79 61 89 89 61 61 61 61
66 41 41 14 41 41 14 14 14 14
67 95 58 98 58 58 98 98 98 98
68 80 57 99 57 57 99 99 99 99
69 56 97 51 56 56 51 51 51 51
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70 16 16 4 16 16 4 4 4 4
71 72 72 32 72 72 32 32 32 32
72 7 11 45 11 11 45 45 45 45
73 52 71 33 71 71 33 33 33 33
74 87 87 25 87 87 25 25 25 25
75 83 83 8 83 83 8 8 8 8
76 87 84 62 87 87 62 62 62 62
77 78 64 78 9 9 78 78 78 78
78 90 5 90 90 90 90 90 90 90
79 77 77 77 86 86 77 77 77 77
80 65 89 20 89 89 20 20 20 20
81 68 22 27 22 22 27 27 27 27
82 1 1 96 1 1 96 96 96 96
83 24 24 10 24 24 10 10 10 10
84 75 75 8 75 75 8 8 8 8
85 76 76 36 76 76 36 36 36 36
86 43 43 17 43 43 17 17 17 17
87 25 79 2 79 79 2 2 2 2
88 74 74 20 74 74 20 20 20 20
89 61 61 51 61 61 51 51 51 51
90 65 80 46 65 65 46 46 46 46
91 14 78 78 14 78 78 78 78 78
92 18 18 50 18 18 50 50 50 50
93 96 96 94 96 96 94 94 94 94
94 50 50 57 50 50 57 57 57 57
95 63 63 93 63 63 93 93 93 93
96 35 35 22 35 35 22 22 22 22
97 93 93 82 93 93 82 82 82 82
98 59 59 41 59 59 41 41 41 41
99 82 82 67 82 82 67 67 67 67
100 33 33 68 33 33 68 68 68 68
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Table D.2: Controllers chosen by different metrics for rocuronium models
Patient Model Switching Ref Track Alpha Gamma Uss Norm2 Vinnicombe Impulse Step
1 23 23 17 23 23 17 17 17 17
2 31 16 33 16 16 33 33 33 33
3 34 6 12 6 6 12 12 12 12
4 2 16 18 16 16 18 18 18 18
5 5 5 15 5 5 15 15 15 15
6 5 5 25 15 15 25 25 25 25
7 19 3 16 3 3 16 16 16 16
8 14 10 35 10 10 35 35 35 35
9 12 26 18 26 26 18 18 18 18
10 35 29 21 29 29 21 21 21 21
11 14 8 17 8 8 17 17 17 17
12 33 33 23 33 33 23 23 23 23
13 22 22 34 31 31 34 34 34 34
14 21 21 30 21 21 30 30 30 30
15 8 8 26 11 11 26 26 26 26
16 6 6 2 6 6 2 2 2 2
17 4 4 7 2 2 7 7 7 7
18 22 2 1 2 2 1 1 1 1
19 34 34 9 34 34 9 9 9 9
20 7 25 23 25 25 23 23 23 23
21 33 33 8 33 33 8 8 8 8
22 14 14 10 14 14 10 10 10 10
23 13 31 11 31 31 11 11 11 11
24 1 1 12 30 30 12 12 12 12
25 32 32 29 32 32 29 29 29 29
26 30 20 6 20 20 6 6 6 6
27 23 9 15 9 9 15 15 15 15
28 12 12 14 12 12 14 14 14 14
29 31 19 29 34 34 29 29 29 29
30 10 10 25 10 10 25 25 25 25
31 26 24 35 24 24 35 35 35 35
32 23 23 36 13 13 36 36 36 36
33 25 25 23 25 25 23 23 23 23
34 21 12 2 12 12 2 2 2 2
35 19 19 13 19 19 13 13 13 13
36 10 30 8 30 30 8 8 8 8
37 25 33 32 25 1 32 32 32 32
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Real Case Reports
The reports from the real cases acquired during surgeries are developed by the software Moni-
toring and Control in Anesthesia (see Appendix B). These reports provide a summary from the
surgeries where the switching strategy was applied, once the Gender, Age, Height and Weight
from the patient, the name of the surgery, the protocol used by the anesthesiologist, and the
controllers used during the surgery can be promptly seen, and any variable acquired with the
software Datex SAD - Data Acquisition (see Appendix B) during the surgery can be plotted.
Also, this report allows an access to all the information collected in the Special Notes Tab of the
Datex SAD - Data Acquisition software (for more details see Appendix B).
This tool is very important to provide quick information, easily interpreted by the user. The
whole surgery can be easily summarized and, most important, the NMB level control can be
easily explained and described through these reports.
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Figure E.1: Report from a real case acquired at ULSM-HPH (2012/03/29 Case 2)
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Figure E.2: Report from a real case acquired at ULSM-HPH (2012/04/12 Case 1).
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Figure E.3: Report from a real case acquired at ULSM-HPH (2012/04/12 Case 2).
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Figure E.4: Report from a real case acquired at ULSM-HPH (2012/05/10 Case 2).
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Figure E.5: Report from a real case acquired at ULSM-HPH (2012/05/31 Case 1).
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